var title_f33_21_34128="Mental crease";
var content_f33_21_34128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mental crease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A horizontal groove is present on the chin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_21_34128=[""].join("\n");
var outline_f33_21_34128=null;
var title_f33_21_34129="Turner syndrome growth chart";
var content_f33_21_34129=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75558&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Growth chart for children with Turner syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 500px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Reiser, P, Davenport, M. Turner syndrome: A guide for families. Turner Syndrome Society of the United States, Houston, TX 2002. Copyright &copy; 2002 Turner Syndrome Society-US.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_21_34129=[""].join("\n");
var outline_f33_21_34129=null;
var title_f33_21_34130="Strawberry gallbladder Gross";
var content_f33_21_34130=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gallbladder cholesterolosis (strawberry gallbladder)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surgical specimen from a patient with gallbladder cholesterolosis. The lipid accumulation on a background of hyperemic mucosa gives it the appearance of a strawberry.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Salam F Zakko, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_21_34130=[""].join("\n");
var outline_f33_21_34130=null;
var title_f33_21_34131="Anidulafungin: Patient drug information";
var content_f33_21_34131=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Anidulafungin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/51/20276?source=see_link\">",
"     see \"Anidulafungin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2649581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Eraxis&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5939463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Eraxis&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat yeast infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701525",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to anidulafungin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11465 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_21_34131=[""].join("\n");
var outline_f33_21_34131=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2649581\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5939463\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026611\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026610\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026615\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026616\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026618\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026613\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026620\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/51/20276?source=related_link\">",
"      Anidulafungin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_21_34132="Dextromethorphan: Pediatric drug information";
var content_f33_21_34132=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dextromethorphan: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?17/46/18150?source=see_link\">",
"    see \"Dextromethorphan: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/18/29988?source=see_link\">",
"    see \"Dextromethorphan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Creo-Terpin&reg; [OTC];",
"     </li>",
"     <li>",
"      Creomulsion&reg; Adult Formula [OTC];",
"     </li>",
"     <li>",
"      Creomulsion&reg; for Children [OTC];",
"     </li>",
"     <li>",
"      Delsym&reg; [OTC];",
"     </li>",
"     <li>",
"      Father John's&reg; [OTC];",
"     </li>",
"     <li>",
"      Hold&reg; DM [OTC];",
"     </li>",
"     <li>",
"      Nycoff [OTC];",
"     </li>",
"     <li>",
"      PediaCare&reg; Children's Long-Acting Cough [OTC];",
"     </li>",
"     <li>",
"      Robafen Cough [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Children's Cough Long-Acting [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Lingering Cold Long-Acting Cough [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Lingering Cold Long-Acting CoughGels&reg; [OTC];",
"     </li>",
"     <li>",
"      Scot-Tussin&reg; Diabetes [OTC];",
"     </li>",
"     <li>",
"      Silphen-DM [OTC];",
"     </li>",
"     <li>",
"      Triaminic&reg; Children's Cough Long Acting [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; 44&reg; Cough Relief [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; DayQuil&reg; Cough [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Nature Fusion&trade; Cough [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antitussive",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cough Preparation",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?17/46/18150?source=see_link\">",
"      see \"Dextromethorphan: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage in children &lt;4 years of age is not well established; Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 months: 0.5-1 mg every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3-6 months: 1-2 mg every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7 months to 1 year: 2-4 mg every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;2-6 years: 2.5-7.5 mg every 4-8 hours; extended release formulation: 15 mg twice daily (maximum: 30 mg/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 years: 5-10 mg every 4 hours or 15 mg every 6-8 hours; extended release formulation: 30 mg twice daily (maximum: 60 mg/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;12 years and Adults: 10-30 mg every 4-8 hours or extended release formulation: 60 mg twice daily (maximum: 120 mg/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F158835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid filled, oral, as hydrobromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robafen Cough: 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robitussin&reg; Lingering Cold Long-Acting CoughGels&reg;: 15 mg [contains coconut oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as hydrobromide: 15 mg/5 mL (120 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Creo-Terpin&reg;: 10 mg/15 mL (120 mL) [contains ethanol 25%, tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Scot-Tussin&reg; Diabetes: 10 mg/5 mL (118 mL) [ethanol free, gluten free, sugar free; contains propylene glycol; cherry-strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; 44&reg; Cough Relief: 10 mg/5 mL (120 mL) [contains ethanol, propylene glycol, sodium 28 mg/15 mL, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; Nature Fusion&trade; Cough: 30 mg/30 mL (240 mL) [dye free, ethanol free, gluten free; contains sodium 36 mg/30 mL; honey flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge, oral, as hydrobromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hold&reg; DM: 5 mg (10s) [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hold&reg; DM: 5 mg (10s) [original flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrobromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PediaCare&reg; Children's Long-Acting Cough: 7.5 mg/5 mL (118 mL) [ethanol free; contains sodium 15 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; DayQuil&reg; Cough: 15 mg/15 mL (177 mL, 295 mL) [ethanol free; contains propylene glycol, sodium 15 mg/15 mL; citrus flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delsym&reg;: Dextromethorphan polistirex [equivalent to dextromethorphan hydrobromide] 30 mg/5 mL (89 mL, 148 mL) [ethanol free; contains propylene glycol, sodium 7 mg/5 mL; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delsym&reg;: Dextromethorphan polistirex [equivalent to dextromethorphan hydrobromide] 30 mg/5 mL (89 mL, 148 mL) [ethanol free; contains propylene glycol, sodium 7 mg/5 mL; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as hydrobromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Creomulsion&reg; Adult Formula: 20 mg/15 mL (120 mL) [ethanol free; contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Creomulsion&reg; for Children: 5 mg/5 mL (120 mL) [ethanol free; contains sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Father John's&reg;: 10 mg/5 mL (118 mL, 236 mL) [ethanol free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robitussin&reg; Children's Cough Long-Acting: 7.5 mg/5 mL (118 mL) [ethanol free; contains propylene glycol, sodium 5 mg/5 mL, sodium benzoate; fruit-punch flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robitussin&reg; Lingering Cold Long-Acting Cough: 15 mg/5 mL (118 mL) [contains ethanol 1.4%, menthol, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silphen-DM: 10 mg/5 mL (120 mL) [strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Triaminic&reg; Children's Cough Long Acting: 7.5 mg/5 mL (118 mL) [contains benzoic acid, propylene glycol, sodium 7 mg/5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrobromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nycoff: 15 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F158824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer without regard to meals",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of coughs caused by minor viral upper respiratory tract infections or inhaled irritants",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F158878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Benylin&reg; may be confused with Benadryl&reg;, Ventolin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Delsym&reg; may be confused with Delfen&reg;, Desyrel",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F158877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Central nervous system: Confusion, excitement, irritability, nervousness, serotonin syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dextromethorphan or any component; concurrent administration with or within 14 days of discontinuing an MAO inhibitor",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anecdotal reports of abuse of dextromethorphan-containing cough/cold products have increased, especially among teenagers. Healthcare providers should be alert to problems of abuse or misuse as abuse can cause death, brain damage, seizure, loss of consciousness, and irregular heartbeat.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use for persistent or chronic cough, or for cough accompanied by excessive secretions; Creo-Terpin&reg; contains tartrazine which may cause allergic reactions in susceptible individuals; some products may contain sodium benzoate which may cause allergic reactions in susceptible individuals; sodium benzoate has been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites; avoid use of products containing sodium benzoate in neonates. Serotonin syndrome may occur when administered with concomitant proserotonergic drugs (ie, SSRIs/SNRIs or triptans); especially with higher dextromethorphan doses.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F158870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (major), CYP2E1 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F158831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Dextromethorphan. Management: Avoid concurrent use of these agents when possible, unless the increased psychoactive effects of dextromethorphan are desired.  Since codeine activation is also inhibited by quinidine, codeine is unlikely to be suitable as an alternative antitussive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan. Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12708268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal use of standard OTC doses of dextromethorphan when used as an antitussive during the first trimester of pregnancy has not been found to increase the risk of teratogenic effects. Dextromethorphan is metabolized in the liver via CYP2D6 and CYP3A enzymes. The activity of both enzymes is increased in the mother during pregnancy. In the fetus, CYP2D6 activity is low in the fetal liver and CYP3A4 activity is present by ~17 weeks gestation.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1057786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cough, mental status",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Non-narcotic chemical relative of morphine; controls cough by depressing the medullary cough center",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of antitussive action: Within 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Up to 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-Life: 1.4-3.9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 2-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Principally in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1057785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/18/29988?source=see_link\">",
"      see \"Dextromethorphan: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If cough lasts more than 1 week or is accompanied by fever or headache, notify physician",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1057796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dextromethorphan 15-30 mg equals 8-15 mg codeine as an antitussive",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13220 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-1A4E1675F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_21_34132=[""].join("\n");
var outline_f33_21_34132=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158845\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057787\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057780\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158835\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158824\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057791\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057790\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158878\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158877\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057795\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057779\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057778\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158870\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158831\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12708268\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057786\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057777\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057793\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057794\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057785\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057796\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13220\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13220|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?17/46/18150?source=related_link\">",
"      Dextromethorphan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/18/29988?source=related_link\">",
"      Dextromethorphan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_21_34133="Female genital cutting (circumcision)";
var content_f33_21_34133=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Female genital cutting (circumcision)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/21/34133/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/21/34133/contributors\">",
"     Nawal M Nour, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/21/34133/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/21/34133/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/21/34133/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/21/34133/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/21/34133/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female genital cutting, also known as female circumcision or genital mutilation, is a culturally determined practice, predominantly performed in parts of Africa and Asia and affecting more than 130 million women and girls worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/1\">",
"     1",
"    </a>",
"    ]. Recent immigration patterns have caused obstetricians and gynecologists throughout the world to increasingly encounter women who have experienced this practice. It is imperative that these providers understand the health and social issues related to female genital cutting so that they can manage the immediate and long-term complications of the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female genital cutting refers to the manipulation or removal of external genital organs in girls and women. The World Health Organization classified female genital cutting into four types of procedures.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I consists of excision of the prepuce, with or without excision of part or all of the clitoris.",
"     </li>",
"     <li>",
"      Type II involves clitoridectomy and partial or total excision of the labia minora.",
"     </li>",
"     <li>",
"      Type III, or infibulation, includes removing part or all of the external genitalia and reapproximation of the remnant labia majora, leaving a small neointroitus. Type IV involves other forms of injuries to the genital region including pricking, piercing, stretching, burning, scraping or any other manipulation of external genitalia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ORIGINS AND RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The origins of female genital cutting are unknown, but theories as to its origins date back to ancient Egypt, pre-Islamic Arabia, ancient Rome, and Tsarist Russia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. More recently, this practice has come to represent an important rite of passage for girls into womanhood within some cultures. It is thought by some to be a religious custom, but",
"    <strong>",
"     NO",
"    </strong>",
"    religion condones it. It is reinforced by customary beliefs that it maintains a girl's chastity, preserves fertility, ensures marriageability, improves hygiene, and enhances sexual pleasure for men.",
"   </p>",
"   <p>",
"    In Europe and the United States, removal of the clitoris or prepuce was occasionally performed to treat clitoral enlargement, redundancy, hysteria, lesbianism, and erotomania up until the 1930s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the time, circumcision is done with the intention to provide benefit, not cause harm. Parents initiate this procedure with the aim of helping their daughters. Being a wife and a mother is a woman's livelihood in these societies; thus not circumcising one's daughter is equivalent to condemning her to a life of isolation. Infibulation safeguards her virginity, preserves her chastity, and ensures her eligibility for marriage, thereby protecting her future.",
"   </p>",
"   <p>",
"    Many women who have undergone female genital cutting do not consider themselves to be mutilated. They do not believe that they are being selectively tortured because the majority of women in their community have gone through this ritual. Those who immigrate to the United States from refugee camps may be surprised to learn that most women here are not circumcised. Therefore, these women can be offended if they are referred to as having undergone genital mutilation. Instead, it is better to use the term circumcision, genital cutting, or the exact word they use in their language. Women who have undergone female genital cutting have voiced concern that health care providers are not sensitive when broaching this subject and sometimes must be educated about this practice by the patient herself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circumcision is performed between the ages of 5 and 12, in some places during a celebration in which the girl receives gifts of money, gold, and clothes. Invited families and friends often bring food and music to the festivities. In other regions, however, girls are abducted in the middle of the night to be circumcised.",
"   </p>",
"   <p>",
"    Nonmedically trained operators usually perform female genital cutting. Anesthesia and antibiotics are rarely administered. The instruments used may be old, rusty knives, razors, scissors, or heated pebbles, which are rarely washed between procedures. Hemostasis is assured by catgut sutures, thorns, or homemade adhesive concoctions such as sugar, egg, or animal excrement. The girl's legs are bound around the ankles and thighs for approximately one week after the procedure, and she is kept in bed.",
"   </p>",
"   <p>",
"    However, some circumcisions are done under sterile conditions with appropriate instruments. An anesthetic may be administered when the procedure is performed in major cities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COMPLICATIONS AND OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are both short and long-term complications related to this procedure. However, health care providers should be aware that circumcised women present with a variety of complaints and their circumcision is not necessarily the problem. It is also important to stress that not all women suffer complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Periprocedural complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical precision can be compromised by lack of anesthesia, the struggles of the child held forcibly in the lithotomy position, and the experience of the operator. Success is often dependent upon chance, rather than accuracy. Early post-procedure complications thus include hemorrhage, infection, oliguria, and sepsis (",
"    <a class=\"graphic graphic_table graphicRef74122 \" href=\"mobipreview.htm?33/25/34203\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Long-term gynecological issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have undergone type II or III female genital cutting tend to suffer more long-term complications than those who have undergone type I or IV.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common long-term complications are dysmenorrhea, dyspareunia, and chronic vaginal infections. Other complications are related to voiding (",
"      <a class=\"graphic graphic_table graphicRef69496 \" href=\"mobipreview.htm?42/26/43435\">",
"       table 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/8\">",
"       8",
"      </a>",
"      ]. Meatal obstructions and urinary strictures could develop if the urethral meatus was inadvertently injured. Affected women complain of straining, urinary retention, or a slow urinary stream. An infibulated scar can also result in the urine becoming stagnant, thereby facilitating the ascent of bacteria into the urethra. Infibulated women are thus at higher risk for meatitis, urinary stones, and chronic urinary tract infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other complications from scarring include fibrosis, keloids, sebaceous (epidermal) cysts, vulvar abscesses, and partial or total fusion of the labia minora or majora. The latter complication can lead to hematometra or hematocolpos. In addition, a small neointroitus may cause vaginismus, chronic vaginal infection, and neuromas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/46/31464?source=see_link\">",
"       \"Vulvar abscess\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The infertility rate is higher in circumcised women compared to the general population (25 to 30 versus 8 to 14 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/13\">",
"       13",
"      </a>",
"      ]. The frequency of infertility appears to correlate with the anatomical extent of female genital cutting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/14\">",
"       14",
"      </a>",
"      ]. Introital and vaginal stenosis create a physical barrier; thus, couples may attempt coitus for months before completing penetration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/15\">",
"       15",
"      </a>",
"      ]. Failure to succeed and persistent dyspareunia can lead to apareunia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/16\">",
"       16",
"      </a>",
"      ]. Infertility may also be related to tubal damage from ascending infection related to the procedure.",
"     </li>",
"     <li>",
"      Sexual satisfaction has been difficult to ascertain because of the sensitive nature of the topic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/17\">",
"       17",
"      </a>",
"      ]. One survey that interviewed circumcised women reported they were able to achieve orgasm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/18\">",
"       18",
"      </a>",
"      ]. However, a study of 1836 circumcised Nigerian women found that the procedure (type 1 and II) did not attenuate sexual feelings or frequency of intercourse and was associated with a higher prevalence of abnormal vaginal discharge and pelvic pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/19\">",
"       19",
"      </a>",
"      ]. Another study also showed that those who had undergone type III infibulation were significantly affected in terms of sex drive, arousal and orgasm when compared with those who had undergone a type I procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Obstetrical issues",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Monitoring labor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progress of labor is typically monitored using serial cervical examinations. Performing a pelvic exam on an infibulated woman can be challenging. The narrow neointroitus can make a bimanual exam difficult, if not impossible. Obstetricians face the dilemma of either defibulating the woman early in labor or monitoring the labor via rectal exam. Neither of these is an optimum solution: early defibulation (reversal of infibulation) would require a very early epidural and irritation of the incision with every cervical assessment, while rectal examination of the cervix is uncomfortable and most obstetricians have no experience using this technique in labor. However, inaccurate cervical assessment is also problematic because latent phase of labor may be falsely diagnosed as active labor and lead to an unnecessary cesarean delivery. Other challenges include difficulties placing a fetal scalp electrode, intrauterine pressure catheter, or Foley catheter and performing fetal scalp pH.",
"   </p>",
"   <p>",
"    The infibulated scar can prolong only the second stage of labor, probably because the scar may obstruct crowning and delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/21\">",
"     21",
"    </a>",
"    ]. A defibulation procedure during the second trimester is strongly recommended to prevent this problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pregnancy outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A WHO study group compared obstetrical outcomes of women with and without female genital cutting (FGC) (n = 7171 no FGC, 6856 FGC 1, 7771 FGC II, 6595 FGC III) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/23\">",
"     23",
"    </a>",
"    ]. Women with FGC II and III, but not FGC I, were at significantly higher risk of cesarean delivery, postpartum hemorrhage, and extended maternal hospital stay, and their infants were at significantly higher risk of requiring resuscitation and of dying in the hospital than women without FGC. The risks were higher in women with FGC III than FGC II. Nulliparous and parous women with FGC I, II, and III had higher rates of episiotomy and perineal tears than women without FGC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DEFIBULATION COUNSELING AND PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women seek defibulation because they are pregnant or planning pregnancy, or because of",
"    <span class=\"nowrap\">",
"     apareunia/dyspareunia,",
"    </span>",
"    dysmenorrhea, or difficulty urinating [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimum time to defibulate a woman is prior to coitus to prevent dyspareunia or prior to pregnancy to prevent obstetric complications. What is medically beneficial to the woman, however, may not necessarily be the best time for her. As discussed above, one of the reasons for female circumcision is to ensure virginity. Therefore, these women may prefer to marry and prove their virginal status prior to defibulation.",
"   </p>",
"   <p>",
"    Defibulation can be performed during pregnancy. A woman may require multiple prenatal visits before she finally consents to the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/22\">",
"     22",
"    </a>",
"    ]. Counseling her about the risks of delivery with an infibulated scar is critical; the risks (eg, bleeding, infection, scar formation, preterm labor) and benefits of defibulation must also be reviewed and she should be aware that her urinary stream will feel different (increased).",
"   </p>",
"   <p>",
"    Surgery during the second trimester under regional anesthesia decreases both obstetrical and fetal risks. General anesthesia is an alternative, but local anesthesia is not a good choice because women sometimes develop flashbacks from their circumcision.",
"   </p>",
"   <p>",
"    Positive outcomes have been reported following defibulation or reconstructive surgery following genital cutting. As an example, a prospective study of 2938 women with type II or III female genital cutting who underwent mobilization of the clitoral stump reported that complications occurred in 5 percent of patients. Among the 866 patients who completed a one-year postoperative assessment, 97 percent had no change or an improvement in sexual pain and clitoral pleasure. In addition, a series of 32 patients who underwent defibulation reported that all of the women and their husbands were satisfied with the results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infibulated scar is a flap obstructing the introitus and urethra that must be excised. The steps in the procedure are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Place regional or general analgesics and long-acting local anesthesia.",
"     </li>",
"     <li>",
"      Insert a Kelly clamp under the scar to delineate its length (",
"      <a class=\"graphic graphic_picture graphicRef54998 \" href=\"mobipreview.htm?18/21/18772\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Palpate anteriorly to assess whether the clitoris is buried under the scar.",
"     </li>",
"     <li>",
"      Place two Allis clamps along the infibulated scar.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Make an anterior incision between the two Allis clamps with Mayo scissors, being certain not to cut into a buried clitoris (",
"    <a class=\"graphic graphic_picture graphicRef69572 \" href=\"mobipreview.htm?27/59/28595\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79801 \" href=\"mobipreview.htm?31/7/31859\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal is to view the introitus and urethra easily (",
"      <a class=\"graphic graphic_picture graphicRef56234 \" href=\"mobipreview.htm?10/26/10660\">",
"       picture 4",
"      </a>",
"      ). There is no need to incise too anteriorly towards the clitoral region.",
"     </li>",
"     <li>",
"      Place (4-0) subcuticular sutures on each side (",
"      <a class=\"graphic graphic_picture graphicRef69034 \" href=\"mobipreview.htm?22/33/23059\">",
"       picture 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef80038 \" href=\"mobipreview.htm?33/15/34035\">",
"       picture 6",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Postoperatively, instruct the patient to take sitz baths twice each day.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    cream (2 percent) can be applied after the sitz bath. Opioid analgesics taken as needed for one or two days is usually adequate for postoperative pain control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A treatment technique using carbon dioxide laser surgery has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     REINFIBULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women who have just given birth will request immediate reinfibulation. The procedure may create the long-term complications previously mentioned and should be strongly discouraged. The woman may only feel comfortable being infibulated; her request should be respected. The United States passed a law in March 1997 that made performing any medically unnecessary surgery on the genitalia of a girl younger than 18 years of age a federal crime. However, reinfibulation was",
"    <strong>",
"     NOT",
"    </strong>",
"    included as a federal crime, so it may be performed with absorbable sutures in a running fashion if a woman strongly insists upon the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are four types of female genital cutting. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The number of African immigrants and refugees coming into the United States is increasing, bringing renewed interest in unique cultural traditions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34133/abstract/28\">",
"       28",
"      </a>",
"      ]. The most important aspect of caring for circumcised women is to develop a trusting relationship. Obstetrician-gynecologists should move beyond the scar and address the woman's health needs, such as pregnancy tests, annual Papanicolaou smears, mammograms, and postmenopausal hormone therapy recommendations. Cultural awareness and sensitivity regarding the procedure are crucial. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Origins and rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential problems after female genital cutting include dysmenorrhea, dyspareunia, chronic vaginal and bladder infections, voiding difficulties, fibrosis, keloids, sebaceous cysts, vulvar abscesses, infertility, and difficulty with pelvic examinations, coitus, and vaginal delivery. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Complications and outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest defibulation prior to coitus to prevent dyspareunia or prior to pregnancy to prevent problems with vaginal delivery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Defibulation counseling and procedure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Female Genital Mutilation. A joint WHO/UNICEF UNFPA statement. World Health Organization 1997.",
"    </li>",
"    <li>",
"     www.who.int/mediacentre/factsheets/fs241/en/index.html. (Accessed 3/21/2006).",
"    </li>",
"    <li>",
"     Hedley, R, Dorkenoo, E. Child protection and female genital mutilation advice for health, education and social professionals. London: FORWARD, 1992.",
"    </li>",
"    <li>",
"     Hosken, RP. The Hosken Report Genital and Sexual Mutilation of Females. Lexington: Women International Network News, 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/5\">",
"      Shandall AA. Circumcision and infibulation of females: a general consideration of the problem and a clinical study of the complications in Sudanese women. Sudan Med J 1967; 5:178.",
"     </a>",
"    </li>",
"    <li>",
"     Sheehan, E. Victorian clitoroidectomy. Medical Anthropology Newsletter 1981; 10.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/7\">",
"      Dirie MA, Lindmark G. The risk of medical complications after female circumcision. East Afr Med J 1992; 69:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/8\">",
"      Ozumba BC. Acquired gynetresia in eastern Nigeria. Int J Gynaecol Obstet 1992; 37:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/9\">",
"      Agugua NE, Egwuatu VE. Female circumcision: management of urinary complications. J Trop Pediatr 1982; 28:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/10\">",
"      Nour NM. Urinary calculus associated with female genital cutting. Obstet Gynecol 2006; 107:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/11\">",
"      Toubia N. Female circumcision as a public health issue. N Engl J Med 1994; 331:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/12\">",
"      Fern&aacute;ndez-Aguilar S, No&euml;l JC. Neuroma of the clitoris after female genital cutting. Obstet Gynecol 2003; 101:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/13\">",
"      Macleod, T. Female genital mutilation. J SOGC 1995; 4:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/14\">",
"      Almroth L, Elmusharaf S, El Hadi N, et al. Primary infertility after genital mutilation in girlhood in Sudan: a case-control study. Lancet 2005; 366:385.",
"     </a>",
"    </li>",
"    <li>",
"     El Dareer, A. Women Why Do You Weep? Zed Press, London 1982.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/16\">",
"      Aziz FA. Gynecologic and obstetric complications of female circumcision. Int J Gynaecol Obstet 1980; 17:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/17\">",
"      Andersson SH, Rymer J, Joyce DW, et al. Sexual quality of life in women who have undergone female genital mutilation: a case-control study. BJOG 2012; 119:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/18\">",
"      Lightfoot-Klein H, Shaw E. Special needs of ritually circumcised women patients. J Obstet Gynecol Neonatal Nurs 1991; 20:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/19\">",
"      Okonofu FE, Larsen U, Oronsaye F, et al. The association between female genital cutting and correlates of sexual and gynaecological morbidity in Edo State, Nigeria. BJOG 2002; 109:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/20\">",
"      Thabet SM, Thabet AS. Defective sexuality and female circumcision: the cause and the possible management. J Obstet Gynaecol Res 2003; 29:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/21\">",
"      De Silva S. Obstetric sequelae of female circumcision. Eur J Obstet Gynecol Reprod Biol 1989; 32:233.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Female circumcision/Female Genital Mutilation: Clinical management of circumcised women. American College of Obstetricians and Gynecologists, Washington, DC 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/23\">",
"      WHO study group on female genital mutilation and obstetric outcome, Banks E, Meirik O, et al. Female genital mutilation and obstetric outcome: WHO collaborative prospective study in six African countries. Lancet 2006; 367:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/24\">",
"      Nour NM, Michels KB, Bryant AE. Defibulation to treat female genital cutting: effect on symptoms and sexual function. Obstet Gynecol 2006; 108:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/25\">",
"      Nour NM. Female genital cutting: clinical and cultural guidelines. Obstet Gynecol Surv 2004; 59:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34133/abstract/26\">",
"      Penna C, Fallani MG, Fambrini M, et al. Type III female genital mutilation: clinical implications and treatment by carbon dioxide laser surgery. Am J Obstet Gynecol 2002; 187:1550.",
"     </a>",
"    </li>",
"    <li>",
"     Federal Prohibition of Female Genital Mutilation Act of 1996. Public Law 104 -140, 11O Stat 1327, 1996.",
"    </li>",
"    <li>",
"     www.brighamandwomens.org/africanwomenscenter. (Accessed 3/21/2006).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3268 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-FC043B0C43-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_21_34133=[""].join("\n");
var outline_f33_21_34133=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ORIGINS AND RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COMPLICATIONS AND OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Periprocedural complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Long-term gynecological issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Obstetrical issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Monitoring labor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pregnancy outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DEFIBULATION COUNSELING AND PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      REINFIBULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3268\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3268|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/21/18772\" title=\"picture 1\">",
"      Defibulation 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/59/28595\" title=\"picture 2\">",
"      Defibulation 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/7/31859\" title=\"picture 3\">",
"      Deinfibulation 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/26/10660\" title=\"picture 4\">",
"      Defibulation 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/33/23059\" title=\"picture 5\">",
"      Defibulation 5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/15/34035\" title=\"picture 6\">",
"      Defibulation 6",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3268|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/25/34203\" title=\"table 1\">",
"      Early complics female circumcis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/26/43435\" title=\"table 2\">",
"      Late complications female circ",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/46/31464?source=related_link\">",
"      Vulvar abscess",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_21_34134="Pubic lice PI";
var content_f33_21_34134=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F64225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F64225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pubic lice",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous lice and nits located around the pubic hair.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_21_34134=[""].join("\n");
var outline_f33_21_34134=null;
var title_f33_21_34135="Thyroid hormone changes cardiac output";
var content_f33_21_34135=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F85918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F85918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 652px\">",
"   <div class=\"ttl\">",
"    Thyroid hormone-mediated changes in cardiac output",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 632px; height: 546px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effects of thyroid hormone on cardiovascular hemodynamics. T3 affects tissue thermogenesis, systemic vascular resistance, blood volume, cardiac contractility, heart rate, and cardiac output as indicated by the arrows.",
"    <div class=\"footnotes\">",
"     Hyper: hyperthyroidism; Hypo: hypothyroidism.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007; 116:1725. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_21_34135=[""].join("\n");
var outline_f33_21_34135=null;
var title_f33_21_34136="Clinical manifestations and diagnosis of retroperitoneal fibrosis";
var content_f33_21_34136=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of retroperitoneal fibrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/21/34136/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/21/34136/contributors\">",
"     Augusto Vaglio, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/21/34136/contributors\">",
"     Carlo Buzio, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/21/34136/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/21/34136/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/21/34136/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/21/34136/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/21/34136/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retroperitoneal fibrosis is a rare condition characterized by the presence of inflammatory and fibrous retroperitoneal tissue that often encases the ureters or abdominal organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/1\">",
"     1",
"    </a>",
"    ]. This disorder was initially called Ormond's disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/2\">",
"     2",
"    </a>",
"    ] but it has also been referred to as periureteritis fibrosa, periureteritis plastica, chronic periureteritis, sclerosing retroperitoneal granuloma, and fibrous retroperitonitis.",
"   </p>",
"   <p>",
"    Retroperitoneal fibrosis may be idiopathic or secondary to other causes. Idiopathic retroperitoneal fibrosis is part of the disease spectrum of \"chronic periaortitis,\" a condition characterized by inflammation and fibrosis surrounding the aorta and iliac arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. Chronic periaortitis also includes inflammatory abdominal aortic aneurysms and perianeurysmal retroperitoneal fibrosis. However, although these entities are grouped together because of similar clinical and histologic characteristics, their pathogeneses and epidemiology may differ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology, pathogenesis, clinical manifestations, and diagnostic evaluation of retroperitoneal fibrosis will be reviewed here. The treatment of retroperitoneal fibrosis is presented separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14904?source=see_link\">",
"     \"Treatment of retroperitoneal fibrosis\"",
"    </a>",
"    ). Other causes of urinary tract obstruction and hydronephrosis are also reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90857066\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retroperitoneal fibrosis is a rare disease. In one Finnish study, the incidence of the idiopathic form of the disease was estimated from hospital discharge data to be 0.1 per 100,000 person-years and its prevalence 1.4 per 100,000 inhabitants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/6\">",
"     6",
"    </a>",
"    ]. However, in a subsequent population-based study performed in the Netherlands, the reported annual incidence was approximately 10-fold higher (ie, 1.3 per 100,000 inhabitants per year) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/7\">",
"     7",
"    </a>",
"    ]. The latter study probably provides a more accurate estimate of the incidence given the complexity of the diagnosis and requirement for prolonged follow-up that would not have been possible in a study of hospital discharge codes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Idiopathic disease most commonly occurs in individuals 40 to 60 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/5,7,9,10\">",
"     5,7,9,10",
"    </a>",
"    ]. Most studies have suggested a 2 to 3:1 male-to-female predominance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/5,7,9,10\">",
"     5,7,9,10",
"    </a>",
"    ], although this is not reported in all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/4\">",
"     4",
"    </a>",
"    ]. One study has suggested that chronic periaortitis, which includes idiopathic retroperitoneal fibrosis, is associated with the HLA allele HLA-DRB1 03 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are idiopathic and secondary forms of retroperitoneal fibrosis, with the former accounting for over 70 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/12\">",
"     12",
"    </a>",
"    ]. A variety of secondary causes of retroperitoneal fibrosis have been identified (",
"    <a class=\"graphic graphic_table graphicRef63911 \" href=\"mobipreview.htm?32/2/32811\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74731 \" href=\"mobipreview.htm?12/44/13003\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/1,3,9,13-15\">",
"     1,3,9,13-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drugs - ergot-derivatives, methysergide (which, in the past, was widely used for the prevention of migraine headaches),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      , beta blockers,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      , analgesics.",
"     </li>",
"     <li>",
"      Malignancy - carcinoid, Hodgkin's and non-Hodgkin&rsquo;s lymphoma, sarcomas, colorectal, breast, prostate and bladder carcinoma.",
"     </li>",
"     <li>",
"      Infections - tuberculosis, histoplasmosis, actinomycosis.",
"     </li>",
"     <li>",
"      Radiation therapy for testicular seminoma, colon, pancreatic cancer.",
"     </li>",
"     <li>",
"      Retroperitoneal hemorrhage.",
"     </li>",
"     <li>",
"      Surgery - lymphadenectomy, colectomy, aortic aneurysmectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, there are reports of cases in association with secondary (AA) amyloidosis, trauma,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema, mesenteric panniculitis and different forms of histiocytosis, particularly Erdheim-Chester disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14440?source=see_link\">",
"     \"Sclerosing mesenteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20680?source=see_link\">",
"     \"Erdheim-Chester disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of idiopathic disease is unclear.",
"   </p>",
"   <p>",
"    There are two leading theories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Idiopathic retroperitoneal fibrosis represents an exaggerated local inflammatory reaction to aortic atherosclerosis, incited by oxidized low density lipoprotein (LDL). This mechanism is supported by the finding in patients with chronic periaortitis (whose spectrum includes idiopathic retroperitoneal fibrosis) of activated T and B lymphocytes in the media and adventitia, high levels of interleukins in aortic wall sections, and circulating antibodies to oxidized LDL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/20-23\">",
"       20-23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Idiopathic retroperitoneal fibrosis is a manifestation of systemic autoimmune disease. This hypothesis is supported by the frequent presence of constitutional symptoms, increased concentrations of acute phase reactants, autoantibodies, and known autoimmune disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other potentially pathogenetic processes described in some patients with idiopathic retroperitoneal fibrosis include large-vessel vasculitis variants, the formation of antibodies to fibroblasts, and the infiltration of IgG4-producing plasma cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of IgG4-producing plasma cells suggests that in some cases, the retroperitoneal fibrosis is a manifestation of IgG4-related disease (IgG4-RD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. IgG4-RD is a multisystem disease characterized by tumor-like swelling of involved organs, a lymphoplasmacytic infiltrate enriched in IgG4-positive plasma cells, and variable degrees of fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13178?source=see_link&amp;anchor=H179281615#H179281615\">",
"     \"Overview of IgG4-related disease\", section on 'Retroperitoneal fibrosis and related disorders'",
"    </a>",
"    .) In most cases of IgG4-RD-associated retroperitoneal fibrosis, other manifestations of the disease are present. As an example, in one report, all 14 of the reported cases of IgG4-related retroperitoneal fibrosis exhibited involvement of other organs, including the pancreas (11 patients), salivary glands (3 patients), lymph nodes (2 patients), pituitary gland (1 patient), and one patient had mediastinal periaortitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/28\">",
"     28",
"    </a>",
"    ]. However, cases of isolated IgG4-related retroperitoneal fibrosis have also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/24\">",
"     24",
"    </a>",
"    ]. IgG4-related disease is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13178?source=see_link&amp;anchor=H179281615#H179281615\">",
"     \"Overview of IgG4-related disease\", section on 'Retroperitoneal fibrosis and related disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retroperitoneal fibrosis has been associated in one report with the HLA-DRB1*03 allele [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial clinical features of idiopathic or secondary retroperitoneal fibrosis are nonspecific and the diagnosis is often not considered until there is significant organ (most commonly kidney) involvement. Most patients have ureteral obstruction and renal impairment by the time they come to medical attention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90857264\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain in the lower back abdomen or flank is the most common presenting symptom among patients with retroperitoneal fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/3\">",
"     3",
"    </a>",
"    ]. In two of the largest retrospective series, pain was present upon presentation in over 90 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. Pain tends to be dull and poorly localized and is not affected by activity or posture. Patients may describe bilateral or unilateral flank pain that radiates to the inguinal region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/4\">",
"     4",
"    </a>",
"    ]. Pain may be acute in onset and similar to renal colic; in one study from North America, the diagnosis of retroperitoneal fibrosis was commonly made by radiographic imaging that was done to exclude acute nephrolithiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/11\">",
"     11",
"    </a>",
"    ]. Pain is often relieved better with nonsteroidal antiinflammatory agents than opiates, probably due to the inflammatory nature of the lesion.",
"   </p>",
"   <p>",
"    Pain is often associated with systemic complaints including malaise, anorexia, weight loss, moderate fever, nausea, and vomiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In the study cited above, among 48 patients, fatigue and often substantial weight loss were present upon presentation in 29 and 26 patients (60 and 54 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/4\">",
"     4",
"    </a>",
"    ]. Other symptoms included anorexia (8 patients), fever (2 patients) and testicular pain (4 patients).",
"   </p>",
"   <p>",
"    Similar findings were noted in another series from the Netherlands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/7\">",
"     7",
"    </a>",
"    ]. Among 53 patients, lower back, abdominal, flank and testicular pain were present in 32, 30, 28 and 19, respectively. Weight loss, constipation, nausea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting, and fever were present in 21, 16, 13, and 9 patients respectively.",
"   </p>",
"   <p>",
"    Testicular pain was noted in more than 50 percent of male patients in one randomized trial of 40 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients may describe upper leg claudication related to arterial compromise of the lower extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/1,7\">",
"     1,7",
"    </a>",
"    ] or symptoms of mesenteric ischemia due to compression of the mesenteric arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/1,3,10,31-33\">",
"     1,3,10,31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The urine output may be reduced, normal, or even increased (due to a secondary concentrating defect) in patients with obstructive uropathy. Gross hematuria is uncommon but urgency, urinary frequency and dysuria are commonly described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On physical examination, patients may be hypertensive due to renal artery impingement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/3,10,31-33\">",
"     3,10,31-33",
"    </a>",
"    ]. In the study from the Netherlands, hypertension was present in 57 percent of patients on presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/7\">",
"     7",
"    </a>",
"    ], and in the study from North America,",
"    <strong>",
"     new onset",
"    </strong>",
"    hypertension (which may be more likely to be related to retroperitoneal fibrosis) was present among 33 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients may have lower extremity edema or evidence of thrombophlebitis or deep vein thrombosis resulting from obstruction of the inferior vena cava",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    iliac veins. Lower extremity edema was present on presentation among 11 of 48 patients (23 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/4\">",
"     4",
"    </a>",
"    ]. A hydrocele, which is a collection of peritoneal fluid between the parietal and visceral layers of the tunica vaginalis, is not uncommon among patients with retroperitoneal fibrosis. In the study from the Netherlands, a hydrocele was noted among 29 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/7\">",
"     7",
"    </a>",
"    ], and in the randomized trial cited above, testicular pain, varicocele or hydrocele was present in 55 to 58 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/5\">",
"     5",
"    </a>",
"    ]. Formation of hydroceles and varicoceles is likely related to compression of retroperitoneal vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no hematologic or biochemical abnormalities that are specific for retroperitoneal fibrosis. A variable elevation in the serum BUN and creatinine concentration is usually observed, depending upon the presence and extent of obstruction. Among 40 patients with newly diagnosed retroperitoneal fibrosis, 72 to 78 percent had evidence of ureteral obstruction and 44 to 50 percent had renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/5\">",
"     5",
"    </a>",
"    ]. In the Netherlands study, impaired renal function (defined as serum creatinine greater than 1.2",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    was present in 66 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The urinary sediment is most often normal.",
"   </p>",
"   <p>",
"    The erythrocyte sedimentation rate and C-reactive protein are elevated in the majority of patients at presentation reflecting the inflammatory nature of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/7,34\">",
"     7,34",
"    </a>",
"    ]. As an example, among 53 patients in the Netherlands study cited above, 74 and 62 percent had an elevated ESR and C-reactive protein, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/7\">",
"     7",
"    </a>",
"    ]. An elevated antinuclear antibody may be present in up to 60 percent, and many have anemia possibly related to renal insufficiency or chronic inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/1,35,36\">",
"     1,35,36",
"    </a>",
"    ]. Among 48 patients in the series from North America that is cited above, 18 had hemoglobin concentration below 11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/4\">",
"     4",
"    </a>",
"    ] and normocytic anemia was noted among 64 percent of patients in the Netherlands study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/7\">",
"     7",
"    </a>",
"    ]. Other less common abnormalities include leukocytosis and eosinophilia.",
"   </p>",
"   <p>",
"    There are reports of associated monoclonal or polyclonal dysproteinemias. In one such report, all five affected patients had immunoglobulin heavy chain gene rearrangement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1736381575\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal ultrasonography is often the first procedure performed because of its common use to detect possible urinary tract obstruction in patients with unexplained renal insufficiency. Ultrasonography usually reveals a poorly marginated, periaortic mass that is typically echo-free or hypoechoic and may be associated with hydronephrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/38\">",
"     38",
"    </a>",
"    ]. As noted above, hydronephrosis is detected on presentation in a significant number of patients. In one randomized trial, 72 to 78 percent of newly diagnosed patients had unilateral or bilateral obstruction diagnosed by radiographic imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are, however, limitations to the use of ultrasonography. Body habitus, bowel gas, and adjacent bony structures may impair visualization of the fibrotic mass and only hydronephrosis may be apparent, similar to that seen in any form of obstruction (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77938 \" href=\"mobipreview.htm?10/0/10246\">",
"     image 1",
"    </a>",
"    ). It is thus not the optimal imaging study for the diagnosis of retroperitoneal fibrosis. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of retroperitoneal fibrosis may be suspected from the characteristic pain but is more often detected as part of the evaluation for urinary tract obstruction or venous or arterial insufficiency. The diagnosis is often made by imaging studies. The imaging study of choice is a CT scan, which often shows pathognomonic findings. However a definitive diagnosis may require a biopsy. It is controversial whether all patients whose CT suggests retroperitoneal fibrosis require a biopsy to confirm the diagnosis and exclude malignancy as a cause. Many clinicians do not perform a biopsy in patients with a CT scan demonstrating findings typical of retroperitoneal fibrosis, unless the patient is having surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. However, this requires local expertise in making the radiographic diagnosis. We suggest a biopsy in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The location of the mass is atypical.",
"     </li>",
"     <li>",
"      Clinical, laboratory or radiologic findings suggest the presence of an underlying malignancy or infection.",
"     </li>",
"     <li>",
"      Local experience with retroperitoneal fibrosis is limited.",
"     </li>",
"     <li>",
"      The patient does not respond to initial therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14904?source=see_link\">",
"       \"Treatment of retroperitoneal fibrosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1736383196\">",
"    <span class=\"h2\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast-enhanced CT scan is the examination of choice to visualize the extent of fibrosis, and to assess the presence of lymphadenopathy and tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Retroperitoneal fibrosis assessed by CT scan exhibits similar attenuation numbers to that of muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/41\">",
"     41",
"    </a>",
"    ]. The mass is confluent, encasing (but not displacing) the anterior and lateral sides of the aorta and often encircling and compressing the inferior vena cava (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55419 \" href=\"mobipreview.htm?0/39/625\">",
"     image 2",
"    </a>",
"    ). Localized lymphadenopathy adjacent to the mass is observed in about 25 percent of the cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT scan offers the additional advantage of enabling CT-guided biopsy to obtain tissue for pathologic analysis. This can be done concurrently if the diagnosis is suspected prior to the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tissue for pathologic examination may be obtained either via CT-guided core biopsy or as an open (surgical) procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/3,40,42\">",
"     3,40,42",
"    </a>",
"    ]. An open biopsy is preferred if the patient is to have surgery to relieve obstruction, and must be performed if the results of the CT-guided core biopsy are inconclusive.",
"   </p>",
"   <p>",
"    When performed, CT (or other imaging modalities such as ultrasound or MRI) should assess renal vessel involvement; this is often an overlooked feature of the disease but is found in up to one third of the cases and may also require interventional procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1736383203\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic findings in idiopathic and secondary retroperitoneal fibrosis are sometimes indistinguishable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/1\">",
"     1",
"    </a>",
"    ]. Macroscopically, a hard, white plaque of varying thickness is seen. Typically, this is found around the abdominal aorta and iliac vessels, as well as the inferior vena cava and the ureters. Microscopically, there is sclerosis and infiltration of mononuclear cells in varying proportions, depending on the stage of disease, with sclerosis more prominent in later stages of disease. The inflammatory infiltrate consists of B and T lymphocytes, macrophages, and plasma cells, and may be diffuse or arranged in pseudo-nodular, perivascular aggregates. The latter usually have a core rich in CD20+ B-cells and a periphery rich in CD3+ T-cells, with a CD4 to CD8 ratio of 3:1. Most plasma cells are positive for IgG4. Patients with retroperitoneal fibrosis associated with IgG4-related disease have an abundance of IgG4+ plasma cells. Among 14 patients with newly diagnosed idiopathic retroperitoneal fibrosis, 4 had extensive IgG4+ plasma cell infiltration but no patient had evidence of extraperitoneal IgG4-related disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional histologic features of idiopathic retroperitoneal fibrosis include vasculitis of small retroperitoneal vessels (about one half of the cases) and hyaline rinds surrounding small retroperitoneal vessels and nerves. The prominent fibrous tissue consists of type I collagen and includes an abundant population of fibroblasts, some of which are myofibroblasts, suggesting an activated phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1736383093\">",
"    <span class=\"h2\">",
"     Other diagnostic tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1736381237\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) in retroperitoneal fibrosis produces findings comparable to those with CT scanning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/44\">",
"     44",
"    </a>",
"    ]. Advantages of MRI include the avoidance of contrast. It has also been proposed that an inhomogeneous signal in T2-weighed scans is more suggestive of a malignant process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the administration of gadolinium during magnetic resonance imaging has been strongly linked to an often severe disease called nephrogenic systemic fibrosis among patients with moderate to severe renal disease, particularly those requiring dialysis. As a result, it is recommended that gadolinium-based imaging be avoided, if possible, in patients with an estimated glomerular filtration rate less than 30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    There is no consensus among experts concerning the decision to administer gadolinium among patients with an estimated GFR between 30 and 60",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1736381251\">",
"    <span class=\"h3\">",
"     Intravenous urography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although previously commonly performed, intravenous urography is now rarely used. However, it may be useful in a few cases to fully assess the extent of ureteral involvement and guide therapeutic decisions (eg, ureteral stent placement).",
"   </p>",
"   <p>",
"    Intravenous urography in patients with retroperitoneal fibrosis may demonstrate proximal hydroureteronephrosis, medial deviation of the ureters, and extrinsic compression of the ureters (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67171 \" href=\"mobipreview.htm?0/35/560\">",
"     image 3",
"    </a>",
"    ). Encasement of the ureters prevents dilatation of the middle and distal ureteral segments. Medial deviation of the ureter typically begins at the level of the third and fourth lumbar vertebrae.",
"   </p>",
"   <p>",
"    However, these classic findings are not observed in all patients with retroperitoneal fibrosis, and medial deviation of the ureter may be found in some normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. One study, for example, found that almost 20 percent of patients with normal urograms had medial displacement of the ureters without evident urologic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1736381258\">",
"    <span class=\"h3\">",
"     Retrograde or percutaneous antegrade pyelography",
"    </span>",
"    &nbsp;&mdash;&nbsp;These procedures are not routinely used for the diagnosis of retroperitoneal fibrosis because of the efficacy of CT and MRI scans. Retrograde pyelography may demonstrate a smooth tapering of the ureters that is most pronounced at the level of the pelvic brim.",
"   </p>",
"   <p>",
"    Percutaneous antegrade pyeloureterography is a useful therapeutic tool since it can relieve urinary tract obstruction with external drainage. It can also provide visualization of the location and extent of the ureteral obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients present with abdominal or flank pain and renal insufficiency. Among such patients, the major differential diagnosis prior to imaging is nephrolithiasis, which is excluded by CT scan. Patients who present with renal impairment in the absence of renal colic symptoms usually undergo as part of the initial diagnostic evaluation an abdominal or retroperitoneal ultrasound, which demonstrates a retroperitoneal mass with or without hydronephrosis. Among such patients the differential diagnosis includes virtually all malignant and nonmalignant retroperitoneal masses including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphoma or sarcomas. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=see_link\">",
"       \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/23/33146?source=see_link\">",
"       \"Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Retroperitoneal fibromatosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30906?source=see_link\">",
"       \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inflammatory pseudotumor. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/26/43430?source=see_link\">",
"       \"Inflammatory myofibroblastic tumor (plasma cell granuloma) of the lung\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infections such as tuberculosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39673?source=see_link&amp;anchor=H1528649#H1528649\">",
"       \"Clinical manifestations and evaluation of pulmonary tuberculosis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As described above, certain characteristics on CT scan may distinguish retroperitoneal fibrosis from other retroperitoneal lesions. (See",
"    <a class=\"local\" href=\"#H1736383196\">",
"     'CT scan'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, in some cases, other malignant and nonmalignant lesions cannot be excluded radiographically. In such cases, a biopsy should be done to establish the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H243743\">",
"    <span class=\"h1\">",
"     EVALUATION AFTER DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who have a radiologic diagnosis of retroperitoneal fibrosis, causes of secondary retroperitoneal fibrosis should be sought.",
"   </p>",
"   <p>",
"    We review the history for radiation therapy for malignancy and for prior surgeries such as lymphadenectomy, colectomy or aneurysmectomy. We carefully review the medication history, particularly searching for drugs associated with retroperitoneal fibrosis, including ergot-derivatives, methysergide,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    , beta blockers,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    , and analgesics.",
"   </p>",
"   <p>",
"    A CT scan of the chest, abdomen and pelvis is obtained to evaluate for possible malignancies including lymphoma, carcinoid and retroperitoneal sarcomas, and for evidence of infection including tuberculosis, histoplasmosis, and actinomycosis. The further evaluation of patients with radiographic features suggestive of such conditions is discussed elsewhere.",
"   </p>",
"   <p>",
"    Among patients who have no evidence of infection or malignancy, and who have a history of use of drugs that have been associated with retroperitoneal fibrosis, further evaluation for secondary causes is generally not done.",
"   </p>",
"   <p>",
"    Among patients who have no history of drug exposure, radiation therapy, or prior surgery, and no evidence of infection or malignancy by imaging, we generally perform a biopsy of the retroperitoneal mass to exclude the infections and malignancies listed above, as well as Erdheim-Chester disease.",
"   </p>",
"   <p>",
"    We do not routinely screen for IgG 4-RD unless characteristic signs or symptoms are present (ie, lymphadenopathy or pancreatic enlargement on CT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H121226660\">",
"    <span class=\"h2\">",
"     Positron emission tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) can be a useful metabolic imaging modality for the study of idiopathic retroperitoneal fibrosis. Although its specificity is low since it cannot distinguish between idiopathic and secondary forms of retroperitoneal fibrosis, it may be a reliable technique to assess the metabolic or inflammatory activity of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/49\">",
"     49",
"    </a>",
"    ]. 18F-FDG PET may lead to early diagnosis of relapses and may also detect diseased sites other than the peri-aortoiliac tissue (eg, mediastinal fibrosis).",
"   </p>",
"   <p>",
"    However, 18F-FDG PET is an expensive examination. Thus, its use may be recommended only at the time of disease onset to screen for other involved sites and assess the inflammatory activity of the mass, and when relapses are suspected but not evident on conventional imaging studies (eg, reappearance of disease-related symptoms in absence of enlargement of the retroperitoneal mass on CT or MRI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34136/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retroperitoneal fibrosis is a rare disease presenting insidiously, often making the diagnosis difficult. Retroperitoneal fibrosis is most often idiopathic, but drugs, infections and malignancies, prior surgeries and radiation therapy for malignancy have been implicated. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of idiopathic retroperitoneal fibrosis is unclear. The two leading theories are that the disease is either an exaggerated local inflammatory reaction to aortic atherosclerosis, or a manifestation of systemic autoimmune disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms may include pain over the flank, lower back, or abdomen, nonspecific systemic complaints, and lower extremity edema. Often, the diagnosis is not considered until a patient is evaluated for obstructive uropathy and renal insufficiency. Most patients have an elevated erythrocyte sedimentation rate or C-reactive protein level. (See",
"      <a class=\"local\" href=\"#H90857264\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of retroperitoneal fibrosis is primarily made via imaging by CT scan but should be confirmed by biopsy in patients who do not have typical findings on CT scan. We also suggest performing a biopsy on patients who have clinical or laboratory abnormalities suggesting infection or malignancy, or if local experience with retroperitoneal fibrosis is limited, or if the patient does not respond to initial therapy.",
"     </li>",
"     <li>",
"      The differential diagnosis of retroperitoneal fibrosis primarily includes other causes of obstructive nephropathy and retroperitoneal masses. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the diagnosis of retroperitoneal fibrosis has been established, secondary causes should be excluded. A history of radiation therapy or prior surgeries such as lymphadenectomy, colectomy or aneurysmectomy should be excluded. Exposure to ergot-derivatives, methysergide,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"       bromocriptine",
"      </a>",
"      , beta blockers,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      , and analgesics should be excluded.",
"      <br/>",
"      <br/>",
"      A CT scan of the chest, abdomen and pelvis should be obtained to evaluate for malignancies and infection. Among patients who have no evidence of infection or malignancy, and who have a history of use of medications that have been associated with retroperitoneal fibrosis, further evaluation for secondary causes is generally not done. Among patients who have no history of radiation therapy, prior surgery, or drug exposure, and no evidence of infection or malignancy by imaging, we generally perform a biopsy of the retroperitoneal mass (if one has not been done already) in order to exclude infections and malignancies and Erdheim-Chester disease. (See",
"      <a class=\"local\" href=\"#H243743\">",
"       'Evaluation after diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/1\">",
"      Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet 2006; 367:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/2\">",
"      ORMOND JK. Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process. J Urol 1948; 59:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/3\">",
"      van Bommel EF. Retroperitoneal fibrosis. Neth J Med 2002; 60:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/4\">",
"      Scheel PJ Jr, Feeley N. Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation. Medicine (Baltimore) 2009; 88:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/5\">",
"      Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet 2011; 378:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/6\">",
"      Uibu T, Oksa P, Auvinen A, et al. Asbestos exposure as a risk factor for retroperitoneal fibrosis. Lancet 2004; 363:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/7\">",
"      van Bommel EF, Jansen I, Hendriksz TR, Aarnoudse AL. Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore) 2009; 88:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/8\">",
"      Vaglio A. Retroperitoneal fibrosis: new insights into clinical presentation and diagnosis. Medicine (Baltimore) 2009; 88:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/9\">",
"      Koep L, Zuidema GD. The clinical significance of retroperitoneal fibrosis. Surgery 1977; 81:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/10\">",
"      Kasales CJ, Hartman DS. Genitourinary case of the day. Retroperitoneal fibrosis. AJR Am J Roentgenol 1994; 162:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/11\">",
"      Martorana D, Vaglio A, Greco P, et al. Chronic periaortitis and HLA-DRB1*03: another clue to an autoimmune origin. Arthritis Rheum 2006; 55:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/12\">",
"      Cronin CG, Lohan DG, Blake MA, et al. Retroperitoneal fibrosis: a review of clinical features and imaging findings. AJR Am J Roentgenol 2008; 191:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/13\">",
"      Graham JR, Suby HI, LeCompte PR, Sadowsky NL. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med 1966; 274:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/14\">",
"      UTZ DC, ROOKE ED, SPITTELL JA Jr, BARTHOLOMEW LG. RETROPERITONEAL FIBROSIS IN PATIENTS TAKING METHYSERGIDE. JAMA 1965; 191:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/15\">",
"      Goenka AH, Shah SN, Remer EM. Imaging of the retroperitoneum. Radiol Clin North Am 2012; 50:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/16\">",
"      Hosaka N, Ito M, Taki Y, et al. Amyloid A gastrointestinal amyloidosis associated with idiopathic retroperitoneal fibrosis. Report of a rare autopsy case and review of the literature. Arch Pathol Lab Med 2003; 127:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/17\">",
"      Jendro MC, Zeidler H, Rosenthal H, et al. Improvement of Erdheim-Chester disease in two patients by sequential treatment with vinblastine and mycophenolate mofetil. Clin Rheumatol 2004; 23:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/18\">",
"      Janssen T, van Cangh PJ. [Retroperitoneal fibrosis due to barium]. Prog Urol 1994; 4:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/19\">",
"      Remmele W, M&uuml;ller-Lobeck H, Paulus W. Primary mesenteritis, mesenteric fibrosis and mesenteric fibromatosis. Report of four cases, pathology, and classification. Pathol Res Pract 1988; 184:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/20\">",
"      Parums DV. The spectrum of chronic periaortitis. Histopathology 1990; 16:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/21\">",
"      Parums DV, Brown DL, Mitchinson MJ. Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med 1990; 114:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/22\">",
"      Vaglio A, Corradi D, Manenti L, et al. Evidence of autoimmunity in chronic periaortitis: a prospective study. Am J Med 2003; 114:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/23\">",
"      Ramshaw AL, Roskell DE, Parums DV. Cytokine gene expression in aortic adventitial inflammation associated with advanced atherosclerosis (chronic periaortitis). J Clin Pathol 1994; 47:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/24\">",
"      Zen Y, Sawazaki A, Miyayama S, et al. A case of retroperitoneal and mediastinal fibrosis exhibiting elevated levels of IgG4 in the absence of sclerosing pancreatitis (autoimmune pancreatitis). Hum Pathol 2006; 37:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/25\">",
"      Hamano H, Kawa S, Ochi Y, et al. Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis. Lancet 2002; 359:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/26\">",
"      Neild GH, Rodriguez-Justo M, Wall C, Connolly JO. Hyper-IgG4 disease: report and characterisation of a new disease. BMC Med 2006; 4:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/27\">",
"      Zen Y, Onodera M, Inoue D, et al. Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol 2009; 33:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/28\">",
"      Stone JR. Aortitis, periaortitis, and retroperitoneal fibrosis, as manifestations of IgG4-related systemic disease. Curr Opin Rheumatol 2011; 23:88.",
"     </a>",
"    </li>",
"    <li>",
"     Witten, DM. Retroperitoneal fibrosis. In: Clinical Urography, Pollack, HM (Ed), WB Saunders, Philadelphia, 1990, p. 2469.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/30\">",
"      Demko TM, Diamond JR, Groff J. Obstructive nephropathy as a result of retroperitoneal fibrosis: a review of its pathogenesis and associations. J Am Soc Nephrol 1997; 8:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/31\">",
"      Littlejohn GO, Keystone EC. The association of retroperitoneal fibrosis with systemic vasculitis and HLA-B27: a case report and review of the literature. J Rheumatol 1981; 8:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/32\">",
"      QUE GS, MANDEMA E. A CASE OF IDIOPATHIC RETROPERITONEAL FIBROSIS PRESENTING AS A SYSTEMIC COLLAGEN DISEASE. Am J Med 1964; 36:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/33\">",
"      Saxton HM, Kilpatrick FR, Kinder CH, et al. Retroperitoneal fibrosis. A radiological and follow-up study of fourteen cases. Q J Med 1969; 38:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/34\">",
"      Magrey MN, Husni ME, Kushner I, Calabrese LH. Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? Arthritis Rheum 2009; 61:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/35\">",
"      Baker LR, Mallinson WJ, Gregory MC, et al. Idiopathic retroperitoneal fibrosis. A retrospective analysis of 60 cases. Br J Urol 1987; 60:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/36\">",
"      Warnatz K, Keskin AG, Uhl M, et al. Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann Rheum Dis 2005; 64:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/37\">",
"      Oshiro H, Ebihara Y, Serizawa H, et al. Idiopathic retroperitoneal fibrosis associated with immunohematological abnormalities. Am J Med 2005; 118:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/38\">",
"      Fagan CJ, Larrieu AJ, Amparo EG. Retroperitoneal fibrosis: ultrasound and CT features. AJR Am J Roentgenol 1979; 133:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/39\">",
"      Feinstein RS, Gatewood OM, Goldman SM, et al. Computerized tomography in the diagnosis of retroperitoneal fibrosis. J Urol 1981; 126:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/40\">",
"      Jois RN, Gaffney K, Marshall T, Scott DG. Chronic periaortitis. Rheumatology (Oxford) 2004; 43:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/41\">",
"      Dalla-Palma L, Rocca-Rossetti S, Pozzi-Mucelli RS, Rizzatto G. Computed tomography in the diagnosis of retroperitoneal fibrosis. Urol Radiol 1981; 3:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/42\">",
"      Amis ES Jr. Retroperitoneal fibrosis. AJR Am J Roentgenol 1991; 157:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/43\">",
"      Corradi D, Maestri R, Palmisano A, et al. Idiopathic retroperitoneal fibrosis: clinicopathologic features and differential diagnosis. Kidney Int 2007; 72:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/44\">",
"      Arriv&eacute; L, Hricak H, Tavares NJ, Miller TR. Malignant versus nonmalignant retroperitoneal fibrosis: differentiation with MR imaging. Radiology 1989; 172:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/45\">",
"      Persky L, Huus JC. Atypical manifestations of retroperitoneal fibrosis. J Urol 1974; 111:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/46\">",
"      Saldino RM, Palubinskas AJ. Medial placement of the ureter: a normal variant which may simulate retroperitoneal fibrosis. J Urol 1972; 107:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/47\">",
"      Emley TE, Cain MP, Faught PR, Davis MM. Ureteropelvic junction obstruction due to inflammatory pseudotumor masquerading as hydronephrosis because of a neuropathic bladder in a child with myelomeningocele. Urology 2001; 58:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/48\">",
"      Stoeckle E, Coindre JM, Bonvalot S, et al. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer 2001; 92:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/49\">",
"      Moroni G, Castellani M, Balzani A, et al. The value of (18)F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis. Eur J Nucl Med Mol Imaging 2012; 39:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/50\">",
"      Salvarani C, Pipitone N, Versari A, et al. Positron emission tomography (PET): evaluation of chronic periaortitis. Arthritis Rheum 2005; 53:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34136/abstract/51\">",
"      Vaglio A, Versari A, Fraternali A, et al. (18)F-fluorodeoxyglucose positron emission tomography in the diagnosis and followup of idiopathic retroperitoneal fibrosis. Arthritis Rheum 2005; 53:122.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7200 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_21_34136=[""].join("\n");
var outline_f33_21_34136=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90857066\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90857264\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1736381575\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1736383196\">",
"      CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1736383203\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1736383093\">",
"      Other diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1736381237\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1736381251\">",
"      - Intravenous urography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1736381258\">",
"      - Retrograde or percutaneous antegrade pyelography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H243743\">",
"      EVALUATION AFTER DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H121226660\">",
"      Positron emission tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7200\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7200|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/0/10246\" title=\"diagnostic image 1\">",
"      Ultrasound showing hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/39/625\" title=\"diagnostic image 2\">",
"      CT scan showing retroperitoneal fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/35/560\" title=\"diagnostic image 3\">",
"      Retrograde pyelogram showing retroperitoneal fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7200|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/2/32811\" title=\"table 1\">",
"      Findings in RP fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/44/13003\" title=\"table 2\">",
"      2ndary Retroperitoneal fibrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/23/33146?source=related_link\">",
"      Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39673?source=related_link\">",
"      Clinical manifestations and evaluation of pulmonary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30906?source=related_link\">",
"      Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/12/20680?source=related_link\">",
"      Erdheim-Chester disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/26/43430?source=related_link\">",
"      Inflammatory myofibroblastic tumor (plasma cell granuloma) of the lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/55/13178?source=related_link\">",
"      Overview of IgG4-related disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/6/14440?source=related_link\">",
"      Sclerosing mesenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14904?source=related_link\">",
"      Treatment of retroperitoneal fibrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_21_34137="Cardiotoxicity of radiation therapy for malignancy";
var content_f33_21_34137=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiotoxicity of radiation therapy for malignancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/21/34137/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/21/34137/contributors\">",
"     Lawrence B Marks, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/21/34137/contributors\">",
"     Louis S Constine, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/21/34137/contributors\">",
"     M Jacob Adams, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/21/34137/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/21/34137/contributors\">",
"     Brian Kavanagh, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/21/34137/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/21/34137/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/21/34137/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/21/34137/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of radiation therapy (RT) has contributed to significant improvements in disease-specific survival for patients with early stage breast cancer, Hodgkin lymphoma (HL), and other malignancies involving the thoracic region. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11770?source=see_link\">",
"     \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=see_link\">",
"     \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These successes with RT, used either alone or in combination with other modalities, resulted in large cohorts of cancer survivors, who are subject to late complications from treatment. Analyses have shown that the therapeutic benefits from RT may be offset to some extent by delayed effects on the heart, thereby reducing the benefits of RT.",
"   </p>",
"   <p>",
"    Irradiation of a substantial volume of the heart to a sufficiently high dose can damage virtually any component of the heart, including the pericardium, myocardium, heart valves, coronary arteries, capillaries, and conducting system. Pericarditis is the typical acute manifestation of radiation injury, while chronic pericardial disease, coronary artery disease, cardiomyopathy, valvular disease, and conduction abnormalities can manifest years or decades after the original treatment. These complications can cause significant morbidity or mortality.",
"   </p>",
"   <p>",
"    The data on the late cardiovascular toxicity of RT come primarily from survivors of breast cancer and HL, diseases in which RT is a frequent component of the initial management and in which survival is often prolonged. Similar effects may be present in other cancer survivors who receive thoracic RT, although data are more limited.",
"   </p>",
"   <p>",
"    An awareness of the potential cardiotoxicity of RT led to the application of improved RT techniques that minimize irradiation to the heart. These contemporary techniques appear to have substantially decreased the incidence of delayed complications, although whether or not there still is some residual risk remains uncertain.",
"   </p>",
"   <p>",
"    The pathophysiology of RT-induced cardiac injury and the clinical data on the magnitude of risk are presented here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiologic pathway responsible for most manifestations of cardiotoxicity appears to involve damage to blood vessels. This injury is thought to be due to the generation of reactive oxygen species that disrupt DNA strands. Secondary inflammatory changes then lead to fibrosis.",
"   </p>",
"   <p>",
"    The histologic hallmarks of radiation-associated cardiotoxicity are diffuse fibrosis in the interstitium of the myocardium with normal-appearing myocytes and narrowing of capillary and arterial lumens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/1\">",
"     1",
"    </a>",
"    ]. Irregularities of the endothelial cell membranes, cytoplasmic swelling, thrombosis, and rupture of the walls are present. The ratio of capillaries to myocytes is reduced by approximately 50 percent, and this leads to myocardial cell death, ischemia, and fibrosis. Dense collagen and fibrin replace the normal adipose tissue of the outer layer of the heart leading to pericardial fibrosis, effusion, and rarely, tamponade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These changes can have several consequences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary artery disease (CAD) results from injury to the intima of the coronary arteries. This initiates a cascade of events that is typical of atherosclerosis, including replacement of damaged cells by myofibroblasts and deposition of platelets [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/1\">",
"       1",
"      </a>",
"      ]. The distribution of arteries affected by RT reflects the dose distribution. As an example, the left anterior descending and the right coronary arteries are most often involved in patients receiving mediastinal RT for HL. Arterial narrowing is typically proximal and often involves the coronary ostia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The cusp",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      leaflets of valves may undergo fibrotic changes with or without calcification. Changes to valves on the left side are more common than those on the right, regardless of the relative dose distribution of RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/5\">",
"       5",
"      </a>",
"      ]. This suggests that the higher pressures in the systemic circulation contribute to the pathogenesis of these lesions.",
"     </li>",
"     <li>",
"      Myocardial fibrosis can compromise cardiac compliance, leading to diastolic dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fibrosis of cells in the conduction system can predispose to dysrhythmia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/7,8\">",
"       7,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of risk factors for the development of RT-induced cardiac toxicity have been identified, including the total radiation dose, the dose per fraction, the volume of heart irradiated, and the concomitant administration of cardiotoxic systemic agents (eg, anthracyclines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    ). Patient-related factors that may increase the risk of radiation-induced cardiotoxicity include younger age at the time of treatment and the presence of other risk factors for coronary heart disease (eg, hypertension, smoking).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BREAST CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incidental radiation to the heart as part of the initial treatment of breast cancer can result in a range of cardiotoxic effects including coronary artery disease, cardiomyopathy, pericardial disease, valvular dysfunction, and conduction abnormalities. Cardiotoxicity is related to both the volume of heart irradiated and the radiation dose delivered to that volume.",
"   </p>",
"   <p>",
"    Older RT techniques for treating the breast, chest wall,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    draining lymph nodes delivered relatively high doses of radiation to the heart. Contemporary techniques deliver less radiation and are associated with a reduced risk of cardiotoxicity. However, it is unclear if there is a &ldquo;safe dose&rdquo; with no increased risk. A recent case controlled study suggested that an increased risk of cardiac disease can be seen after relatively-low doses of radiation (~2 Gy), that the clinical manifestation of this increased risk can be seen throughout a broad continuum of follow-up durations (eg, from &lt;5 years to &ge;20 years), and that the presence of cardiac risk factors markedly increases the baseline risk and the impact of radiation on that risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Despite this, the absolute risk associated with RT is small and appears to be outweighed by the benefits in patients for whom radiation is typically recommended.",
"   </p>",
"   <p>",
"    Randomized trials conducted over the last 30 years demonstrate the overall positive impact of",
"    <span class=\"nowrap\">",
"     post-lumpectomy/mastectomy",
"    </span>",
"    radiation on local control and survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/4\">",
"     4",
"    </a>",
"    ]. These benefits were achieved despite the use of some older radiation techniques. With more modern approaches, the absolute benefits of radiation may be increased, as has been suggested in some reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Initial evidence of cardiovascular toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiovascular toxicity of chest wall irradiation following mastectomy was initially identified in a retrospective analysis of 1461 long-term survivors of breast cancer who were treated from 1949 to 1955 and then followed for up to 34 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/12\">",
"     12",
"    </a>",
"    ]. The women in this cohort had originally been randomly assigned to RT given immediately or delayed RT until the time of a local recurrence. After 15 years, there was a significantly increased mortality in those given immediate RT (relative risk [RR] 1.43) that was attributable to excess deaths from cardiovascular disease.",
"   </p>",
"   <p>",
"    Subsequent meta-analyses confirmed these initial observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. The largest, which explored the impact of RT on breast cancer mortality and on mortality from other causes, was conducted by the Early Breast Cancer Trialists Collaborative Group (EBCTCG), which evaluated 19,582 women enrolled in 40 randomized trials of RT versus no RT that were begun before 1990 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Although the use of RT decreased the annual mortality rate from breast cancer by 13 percent, the annual mortality rate from other causes was increased by 21 percent. The increased nonbreast cancer-related mortality was primarily due to an excess number of deaths from vascular causes (death rate ratio 1.30, compared to those not receiving RT).",
"   </p>",
"   <p>",
"    Most if not all of the individual trials in the meta-analyses were initiated before 1975 and used RT techniques that would now be considered suboptimal because of excessive cardiac irradiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Contemporary RT techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the potential cardiotoxicity of RT was recognized, treatment techniques were modified to minimize incidental cardiac irradiation. Although the data from more recent studies suggest a decreased incidence of cardiotoxicity, the evidence indicates that there is at least some residual risk.",
"   </p>",
"   <p>",
"    Approaches to assessing the relative risk of cardiotoxicity in breast cancer patients treated with modern RT techniques have included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Comparison of the incidence of cardiac morbidity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mortality in those treated with RT (breast or chest wall) compared to those not receiving RT following surgery. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Randomized trials'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Analyses of the effect of radiation dose to the heart on the incidence of cardiac morbidity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mortality. These have included case control studies comparing those who did and did not develop coronary events after RT for breast cancer as well as studies comparing women with left-sided versus right-sided breast cancers (since the dose to the heart is generally less in patients irradiated for right-sided tumors). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Effect of radiation dose to the heart'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Radiographic assessment of cardiac injury following RT. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Surrogate endpoints of myocardial injury'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Randomized trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials conducted by the Danish Breast Cancer Cooperative Group (DBCG 82b and 82c) demonstrated that postmastectomy chest wall irradiation improved survival in high-risk women with breast cancer and that the benefit of chest wall irradiation more than outweighed any increase in cardiac morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=see_link&amp;anchor=H14#H14\">",
"     \"Postmastectomy chest wall irradiation\", section on 'Modern clinical trials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Between 1982 and 1990, 3083 patients with stage II or III primary breast cancer and a high risk of locoregional recurrence were randomly assigned to adjuvant systemic treatment with or without RT following mastectomy. RT included the supraclavicular and axillary lymph nodes, the chest wall, and the internal mammary lymph nodes. A dose of 48 to 50 Gy was delivered in 22 to 25 fractions.",
"   </p>",
"   <p>",
"    The morbidity and mortality from ischemic heart disease associated with RT was assessed in a combined analysis of both trials. At a median follow-up of 10 years, there were no significant differences between irradiated patients and controls with respect to either death or morbidity from ischemic heart disease or acute myocardial infarction.",
"   </p>",
"   <p>",
"    In view of the relatively short follow-up, it remains possible that a difference in cardiotoxicity might become apparent as more women are followed for a longer duration. Furthermore, the analysis did not analyze the incidence of other manifestations of cardiotoxicity, such as heart failure or valvular disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Effect of radiation dose to the heart",
"    </span>",
"    &nbsp;&mdash;&nbsp;There does not appear to be any minimum radiation dose that is entirely safe, and the effects of radiation on the heart increase with increasing doses of radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/9\">",
"     9",
"    </a>",
"    ]. The increased risk can be seen within the first five years and remains elevated for at least 20 years. Women with significant risk factors for an acute coronary event may be at a particularly increased risk.",
"   </p>",
"   <p>",
"    This effect of RT was demonstrated in a population-based case-control study that included 2168 women who were treated for breast cancer with surgery and RT in Sweden and Denmark between 1958 and 2001 . The study included 963 women who experienced a significant coronary event (myocardial infarction, revascularization, or death from ischemic heart disease) following their treatment for breast cancer. These women were compared with 1205 matched controls who received similar therapy for their breast cancer but did not have a cardiac event following breast cancer treatment. Radiation therapy records were reviewed for all patients, and the dose of radiation to the heart estimated for each patient.",
"   </p>",
"   <p>",
"    Results included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was increased risk of major coronary events following RT for all time periods from the period less than five years through greater than 20 years.",
"     </li>",
"     <li>",
"      The estimated mean dose of radiation to the heart was 4.9 Gy; the dose of radiation to the heart was greater in those with a left-sided breast cancer (6.6 Gy versus 2.9 Gy). The risk of a coronary event increased progressively with the radiation dose, with an increase of 7.4 percent for each 1 Gy of radiation to the heart.",
"     </li>",
"     <li>",
"      A history of ischemic heart disease was associated with an increased risk of a cardiac event after treatment for breast cancer (ratio 6.67, p&lt;0.001). Other factors also associated with a significantly increased risk included other circulatory disease, diabetes, or a left sided breast cancer (risk ratios 1.88, 3.23, and 1.32, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only a very limited number of patients received potentially cardiotoxic medications (eg, anthracyclines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    ), which might substantially increase the risk associated with RT. Furthermore, this analysis did not take into account other cardiac complications of radiation (cardiomyopathy, valvular heart disease, arrhythmias). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Other manifestations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additional evidence comes from tumor registry studies that have analyzed the rate of cardiac complications in breast cancer survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/11,14-19\">",
"     11,14-19",
"    </a>",
"    ]. These studies have yielded conflicting results but suggest that there is an increase in cardiac events in women with left-sided breast tumors compared with right-sided cancers, since the latter received lower doses of irradiation to the heart. Two of the larger studies illustrate the potential impact of RT based upon the laterality of the tumor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, outcomes were analyzed from 115,000 women in the SEER database who received adjuvant RT in the United States between 1973 and 2001 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/14\">",
"       14",
"      </a>",
"      ]. For patients irradiated between 1973 and 1982, cardiac mortality was significantly higher in women with left-sided breast cancers and the difference was more pronounced with longer follow-up (cardiac mortality ratio [CMR] for left-sided versus right-sided cancers 1.20, 1.42, and 1.58, for &lt;10, 10-14, and &gt;15 years, respectively). However, for women treated from 1983 to 1992, the differences were less pronounced and not statistically significant, and none of the patients treated from 1993 on had 10-year follow-up. This decrease in excess mortality may reflect improvements in RT techniques, shorter follow-up, or other unknown factors.",
"     </li>",
"     <li>",
"      In a second SEER database study, the risk of death from ischemic heart disease was analyzed in a cohort of 27,283 women with breast cancer whose treatment included adjuvant RT during the period 1973 to 1989 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/11\">",
"       11",
"      </a>",
"      ]. For women diagnosed between 1973 and 1979, there was a significantly higher 15-year mortality rate from ischemic heart disease for women with left-sided versus right-sided tumors (13.1 versus 10.2 percent). For those diagnosed from 1980 to 1984, and from 1985 to 1989, the differences in 15-year mortality rates for women with left-sided versus right-sided tumors were not significant (9.4 versus 8.7 percent and 5.8 versus 5.2 percent, respectively). The overall incidence of death from cardiac disease decreased substantially with the later cohorts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The absolute increase in risk of a major coronary event or death from ischemic heart disease is small. In the case control study comparing women given RT who had a major coronary event with those did not have a coronary event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/10\">",
"     10",
"    </a>",
"    ], the authors calculated that the risk that a 50 year-old women with no other coronary risk factors would die of ischemic heart disease prior to age 80 years would increase from 1.9 to 2.4 percent if she received a mean dose of radiation of 3 Gy to her heart; the risk of having at least one major coronary event would increase from 4.5 to 5.4 percent. If the mean dose to the heart were 10 Gy, the risk of dying would increase from 1.9 to 3.4 percent and the risk of having at least one acute coronary event would increase from 4.5 to 7.7 percent.",
"   </p>",
"   <p>",
"    Numerous other studies, using either overall morbidity and mortality frequencies or less detailed individual patient data, confirm that the effect of radiation on the heart is small compared with the benefit potentially derived from such treatment in appropriately selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/20-26\">",
"     20-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Surrogate endpoints of myocardial injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in the incidence of cardiac morbidity and mortality represent the \"gold standard\" endpoints for evaluating the risk of RT-induced cardiotoxicity. However, there are several drawbacks to this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac injury is a \"late effect\" that may only become apparent many years or even decades after RT. Without prolonged follow-up, cardiac events attributable to RT are unlikely to be observed.",
"     </li>",
"     <li>",
"      Coronary artery disease is frequent in North America and Europe. Thus, analysis of large numbers of patients is required to detect a statistically significant difference in the ratio of observed to expected events in women who have or have not received RT for breast cancer.",
"     </li>",
"     <li>",
"      Competing causes of death (breast cancer itself, other noncardiac causes, age-related illnesses) are likely to obscure any increase in cardiac mortality observed following RT unless a cohort of relatively young, favorable-prognosis breast cancer patients is studied.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To provide an early assessment of possible myocardial injury, studies have used radionuclide myocardial perfusion imaging to look for RT-induced cardiac changes. In the largest prospective series, 160 women were treated with tangential photons to the left breast or chest. Patients underwent serial single-photon emission computed tomography (SPECT)-gated cardiac myocardial perfusion scans for up to six years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although there was intrapatient variability in the presence or absence of perfusion abnormalities over time, the cumulative incidence of perfusion defects increased progressively following treatment. The incidence of at least one study with a perfusion defect was 60 percent at three years. These defects usually persisted at subsequent follow-up times.",
"     </li>",
"     <li>",
"      The incidence of new perfusion defects was related to the volume of myocardium included in the radiation field. &nbsp;When greater than 5 percent of the left ventricle was included in the RT field the incidence of perfusion defects was significantly higher (approximately 55 percent in the first two years versus 25 percent in those with less than 5 percent of the left ventricle in the RT field).",
"     </li>",
"     <li>",
"      The patients with perfusion defects were slightly more likely to have an abnormality in wall motion, but there were no evident reductions in ejection fraction. Thus, the clinical significance of these perfusion defects remains unclear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Smaller retrospective studies from other groups have generated conflicting results, with some showing a similarly high incidence of RT-associated perfusion defects, and others not identifying such an association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. Additional research will be required to establish the long-term clinical and functional significance of these perfusion defects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Breast cancer summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies with RT in breast cancer patients established a link between incidental radiation to the heart and an increase in the frequency of cardiovascular disease. These cardiac effects have been manifested as coronary artery disease (myocardial infarction, need for revascularization, death from ischemic heart disease), cardiomyopathy, pericardial disease, valvular dysfunction, and conduction abnormalities.",
"   </p>",
"   <p>",
"    Improvements in RT technique significantly decreased the amount of incidental radiation received by the heart. These technical advances substantially reduced the incidence of cardiovascular complications compared to older studies. However, cardiovascular complications still appear to be more frequent in patients with left-sided compared to right-sided tumors, suggesting that the risk has not been entirely eliminated.",
"   </p>",
"   <p>",
"    The key factors that appear to influence the risk of delayed cardiovascular toxicity include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The RT field and dose, which determine the amount of incidental irradiation to the heart. As an example, studies that separately analyzed the risk in patients who received internal mammary lymph node irradiation partially or entirely with anterior photon fields found an increased risk of cardiovascular complications compared to those in whom the internal mammary lymph nodes were not included in the field [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Effect of radiation dose to the heart'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The controversy surrounding whether the internal mammary nodes should be included in the radiation field is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39657?source=see_link&amp;anchor=H6#H6\">",
"       \"Techniques of breast and chest wall irradiation for early stage breast cancer\", section on 'The IM nodes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The time interval following RT. Most of the studies that have not found an increased risk of cardiovascular disease were characterized by a follow-up of approximately 10 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/13,15,17,21-23\">",
"       13,15,17,21-23",
"      </a>",
"      ]. In contrast, those analyses that looked at cohorts with longer follow-up have observed an increase in toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/2,11,14,20,23\">",
"       2,11,14,20,23",
"      </a>",
"      ]. Nonetheless, it is possible that the differences observed in these studies reflect further improvements in RT techniques [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Contemporary RT techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other risk factors for cardiovascular disease (hypertension, hyperlipidemia, smoking [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/20\">",
"       20",
"      </a>",
"      ]) and preexisting cardiovascular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/10\">",
"       10",
"      </a>",
"      ] may increase the risk of cardiotoxicity following RT.",
"     </li>",
"     <li>",
"      Particular caution is indicated when RT is used in patients who have or will receive known cardiotoxic agents, such as an anthracycline or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/32\">",
"       32",
"      </a>",
"      ]. The safety of combining RT with agents remains uncertain, and long-term follow-up is required to assess the frequency of late side effects. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42232?source=see_link\">",
"       \"Cardiotoxicity of trastuzumab\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     HODGKIN LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of HL frequently includes supradiaphragmatic RT portals that include portions of the heart, and a number of studies showed that HL survivors have a significantly increased incidence of cardiovascular complications. Clinical manifestations of cardiac toxicity include acute or delayed pericardial disease, myocardial ischemia or infarction, cardiomyopathy, heart failure, valvular abnormalities, or conduction defects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/34/36394?source=see_link&amp;anchor=H11941396#H11941396\">",
"     \"Overview of the approach to the adult survivor of classical Hodgkin lymphoma\", section on 'Cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of HL has evolved in tandem with our understanding of the long-term consequences of treatment, with the goal of decreasing the intensity of therapy without sacrificing long-term disease control. These efforts have included reduction in the volume and dose of incidental cardiac irradiation through modifications in RT techniques, and recognition of the relationship between efficacy and dose and volume in the setting of combined modality therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13512?source=see_link\">",
"     \"Overview of the treatment of classical Hodgkin lymphoma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/6/32874?source=see_link\">",
"     \"Overview of Hodgkin lymphoma in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Incidence of cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant increase in the incidence of cardiovascular disease has been observed in multiple studies of long-term survivors of HL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/33-37\">",
"     33-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cardiotoxic effects of RT in HL survivors were illustrated by a comprehensive analysis of 1474 patients who were treated between 1965 and 1995 according to European Organization for Research and Treatment of Cancer (EORTC) protocols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/33\">",
"     33",
"    </a>",
"    ]. The median age at the start of treatment was 26 years, and the median follow-up was 19 years. The initial treatment consisted of RT only in 28 percent of the patients, chemotherapy alone in 5 percent, and combined RT and chemotherapy in 67 percent. Overall, 84 percent of patients received RT to the mediastinum. The SIRs for various complications were calculated compared to age- and sex-matched incidences in the general population.",
"   </p>",
"   <p>",
"    Key findings included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common cardiovascular diagnoses observed in HL survivors were valvular disorders, angina pectoris, and myocardial infarction. The median time to diagnosis of these cardiac complications was approximately 19 years after treatment. The incidence of each of these complications was significantly elevated, with SIRs between 3 and 5.",
"     </li>",
"     <li>",
"      In a multivariate analysis, mediastinal irradiation significantly increased the risks of coronary heart disease, heart failure, and valvular disorders. Use of anthracyclines further increased the risks of heart failure and valvular disorders associated with mediastinal irradiation.",
"     </li>",
"     <li>",
"      The increased risk of cardiovascular disease persisted for at least 25 years after the initial treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A study of 615 Canadian HL survivors treated between 1988 and 2000 has demonstrated that modern treatment methods continue to be associated with cardiac morbidity, even within 10 to 15 years after therapy. This study also suggested that the risk from combined modality therapy (mediastinal radiotherapy of 30 to 35 Gy and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    of 300",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    was greater than mediastinal radiotherapy alone, although the difference in risk between the two groups was not statistically significant due to small sample size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of cardiovascular complications following RT appears to be even greater when HL patients are treated during childhood. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Pediatric patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mortality from myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have demonstrated that the risk of a fatal myocardial infarction in HL survivors is 2.2- to 7.6-fold greater than in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/34,35,38-42\">",
"     34,35,38-42",
"    </a>",
"    ]. The increased risk of death from myocardial infarction was illustrated by an analysis of 7033 HL survivors treated between 1967 and 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Key observations from this study included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of death from myocardial infarction in this cohort was significantly increased compared to the general population (standardized mortality ratio [SMR] 2.5, 95% CI 2.1-2.9).",
"     </li>",
"     <li>",
"      The increased risk of death from myocardial infarction was limited to those who had received supradiaphragmatic RT or anthracycline-containing chemotherapy. Those whose treatment consisted solely of infradiaphragmatic RT did not have an increase in mortality.",
"     </li>",
"     <li>",
"      The increased risk of death persisted beyond 20 years. This persistence of risk for an extended period has been observed in other studies and appears to be greatest in those treated during childhood [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/40,43\">",
"       40,43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Cardiomyopathy and diastolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irradiation causes fibrosis of the myocardium, which can lead to a restrictive cardiomyopathy. The physiologic correlate of this observation is that mediastinal RT appears to have a greater impact on diastolic rather than systolic cardiac function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/6,44\">",
"     6,44",
"    </a>",
"    ]. This is in contrast to the effects of anthracyclines, which predominantly cause systolic dysfunction. The prevalence of dysfunction varies depending upon RT technique and dose, concomitant use of anthracyclines, length of follow-up, and method of screening.",
"   </p>",
"   <p>",
"    The role of diastolic dysfunction is illustrated by the results of two series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diastolic function was assessed in 282 patients who had previously received a minimum of 35 Gy to the mediastinum for HL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/6\">",
"       6",
"      </a>",
"      ]. Diastolic dysfunction was detected in 40 (14 percent), who had been treated an average of 18 years previously. Exercise-induced ischemia was more common in patients with diastolic dysfunction (23 versus 11 percent in those with normal function).",
"     </li>",
"     <li>",
"      In a series of HL patients who had received prior mediastinal RT, 20 of 37 (54 percent) had echocardiographic evidence of left ventricular dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most importantly, these two studies demonstrated that survivors with diastolic dysfunction have a significantly worse cardiac event-free survival and worse quality of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Valvular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mediastinal RT has been associated with an increased risk of clinically significant valvular abnormalities in 6 to 40 percent of HL survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. Many of the common abnormalities found in HL patients would lead to a recommendation for antibiotic prophylaxis for endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The high frequency of valvular abnormalities is illustrated by two studies that showed that the incidence in HL survivors was increased compared to the incidence in an age- and gender-matched general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One retrospective review evaluated 48 HL survivors who had been diagnosed between the ages of 6 and 25 years and received a median dose of 40 Gy to the mediastinum (36 -44 Gy in 42 of the 48 patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/44\">",
"       44",
"      </a>",
"      ]. Only four patients received an anthracycline as part of their treatment. Median follow-up was 15 years after diagnosis. One or more significant valvular lesions was identified in 43 percent of patients, with the most common lesions being tricuspid regurgitation, mitral regurgitation, or aortic regurgitation (26, 21, and 19 percent respectively).",
"     </li>",
"     <li>",
"      In a study of 294 asymptomatic HL survivors treated 2 to &gt;20 years previously with a mean mantle dose of 43 Gy, survivors had a several-fold increase in the risk of clinically significant valvular disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/45\">",
"       45",
"      </a>",
"      ]. Most striking was a 26 percent incidence of aortic regurgitation &gt;grade 2, which was a 34-fold increase over that expected in this population. The frequency of significant aortic regurgitation, aortic stenosis, and mitral regurgitation each increased with longer follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The valvular disease associated with mediastinal irradiation is slowly progressive and may necessitate lifelong follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. This was illustrated by a series of 116 HL survivors who were originally studied by echocardiography in 1993 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/47\">",
"     47",
"    </a>",
"    ]. At a median follow-up of 10 years, moderate aortic or mitral regurgitation was present in 36 (31 percent). In 2005, 51 patients were reevaluated at a median follow-up of 22 years. Of the 14 patients with no aortic or mitral regurgitation at the 1993 evaluation, 13 (93 percent) had developed a new abnormality. Of the 37 patients with an identified abnormality in 1993, 12 (32 percent) were unchanged and 25 (68 percent) had either worsened or developed a new abnormality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Conduction defects and autonomic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation can cause fibrosis of the conduction pathways in the heart, potentially leading to life-threatening arrhythmias",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    conduction defects years after therapy for HL. Abnormalities observed after mediastinal RT include bradycardia, complete and lesser degrees of heart block, and sick sinus syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/7,8,44\">",
"     7,8,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an electrocardiographic study with a mean follow-up of 15 years, abnormalities were identified in 35 of the 47 survivors who had an ECG (74 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/44\">",
"       44",
"      </a>",
"      ]. The most common findings were conduction delays in the right anterior bundle, which suggests that the anterior structures of the intracardiac conduction system are at greatest risk for fibrosis from mediastinal RT. In addition, 24-hour Holter monitoring suggested a high rate of autonomic dysfunction; 24 of 42 patients (57 percent) had a monotonous heart rate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      loss of circadian variability, while 13 (31 percent) had sustained tachycardia over 24 hours (&gt;90 beats per minute).",
"     </li>",
"     <li>",
"      In another study of 134 childhood cancer survivors evaluated at a mean of five years after treatment, the incidence of ventricular tachycardia was significantly greater in those treated with mediastinal RT, irrespective of anthracycline treatment, compared to healthy controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/8\">",
"       8",
"      </a>",
"      ]. In addition, the frequency of prolonged QT interval was 13 percent in those treated with chest RT alone, 11 percent in those treated with anthracycline chemotherapy alone, and 19 percent in those who had been treated with both RT and anthracyclines.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although pericarditis historically was one of the most common cardiac complications of mediastinal irradiation, it rarely occurs with the lower doses and modern RT techniques currently used. As an example, the incidence of pericarditis decreased from 20 percent to 2.5 percent at one center with the changes in methods of RT administration introduced in the 1970s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Risk factors in HL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factors that influence the risk of cardiac damage in HL patients include the total dose and volume of RT, the dose per fraction, the specific RT technique (ie, the percentage of dose delivered from anteroposterior field as opposed to opposed fields), and the extent to which the coronary arteries are included in the RT field.",
"   </p>",
"   <p>",
"    In addition to treatment-related issues, patient-specific factors that are likely to influence the risk of developing coronary artery disease can be important. These include the patient age at the time of treatment, and the presence of other known cardiac risk factors, such as smoking, high serum cholesterol, and hypertension.",
"   </p>",
"   <p>",
"    The use of combined-modality treatment that includes cardiotoxic chemotherapy such as an anthracycline appears to increase the risk of cardiovascular disease, as illustrated by a study of 1474 HL survivors younger than 41 years at treatment and followed for a median of 19 years. Multivariate analysis showed that the combination of mediastinal RT plus anthracycline-based chemotherapy significantly increased the risk of both heart failure and valvular disorders (HR 2.8 and 2.1, respectively, compared to mediastinal RT alone) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/33\">",
"     33",
"    </a>",
"    ]. The cumulative incidence of heart failure 25 years after combined RT and anthracycline treatment for HL was 7.9 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PEDIATRIC PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term follow-up of pediatric cancer survivors provides evidence that RT is associated with an increased risk of cardiac and cardiovascular mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/51\">",
"     51",
"    </a>",
"    ]. Although this risk is related to the dose of radiation, even relatively low doses appear to increase this risk.",
"   </p>",
"   <p>",
"    A multicenter European study of 4122 cancer survivors who were diagnosed with a solid tumor prior to 1986 provides some of the most extensive data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/52\">",
"     52",
"    </a>",
"    ]. Children with leukemia were excluded. All were younger than 15 years at diagnosis and all were alive at five years after the original diagnosis. The average follow-up was 27 years.",
"   </p>",
"   <p>",
"    Initial treatment included chemotherapy without RT, RT without chemotherapy, or both chemotherapy and RT in 862, 961, and 1909 patients respectively; surgery alone was used in 390 cases. RT treatment planning records were analyzed for the dose of radiation to the heart in 2711 of the 2870 survivors who had received RT (94 percent).",
"   </p>",
"   <p>",
"    Key observations included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall, there were 603 deaths, of which 279 were due to the original cancer. The standardized mortality ratio (SMR) for death due to a cause other than the first cancer was 4.2 compared to the general population. The SMR for cardiac deaths was 5.8 for the entire group of cancer survivors.",
"     </li>",
"     <li>",
"      In a multivariate analysis, the relative risks (RRs) for cardiac death in survivors whose treatment included chemotherapy and in those who had received RT were 7.9 and 7.4, respectively.",
"     </li>",
"     <li>",
"      The RR for cardiac death was proportional to the dose of radiation to the heart, increasing progressively from 3.0 to 25 for cardiac doses of radiation of 1-4.9 Gy to &gt;15 Gy.",
"     </li>",
"     <li>",
"      Analysis of the risk of cardiac mortality in survivors who had received chemotherapy found increases in the relative risk of death in patients who had received an anthracycline, with a statistically nonsignificant trend toward increased mortality in those who had received either a vinca alkaloid or an alkylating agent. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=see_link\">",
"       \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar but larger study of 14,358 five-year survivors of childhood cancer found very similar results in terms of the cardiotoxicity of radiation therapy. Cardiac irradiation of &ge;15 GY increased the relative hazard of congestive heart failure, myocardial infarction, pericarditis and valvular abnormalities by a factor of two to six times higher than non-irradiated survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ESOPHAGEAL CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of patients with locoregional esophageal cancer of the esophagus generally includes RT or chemoradiotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=see_link\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30106?source=see_link\">",
"     \"Management of locally advanced unresectable esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the proximity of the esophagus to the heart, cardiac exposure is unavoidable and can result in high doses of radiation being administered to the heart and pericardium. Cardiotoxicity from RT or chemoradiotherapy can cause benign pericardial effusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/54-56\">",
"     54-56",
"    </a>",
"    ] and may have an adverse effect on the left ventricular ejection fraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential cardiotoxicity of chemoradiotherapy in patients with inoperable esophageal cancer was illustrated by a retrospective series of cases treated between 2000 and 2003 at a single institution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/21/34137/abstract/54\">",
"     54",
"    </a>",
"    ]. Overall, 28 of 101 patients developed a pericardial effusion, with a median time to onset after RT of five months.",
"   </p>",
"   <p>",
"    On multivariate analysis, the only significant dosimetric predictor of risk of pericardial effusion was the percent of pericardium receiving a dose greater than 30 Gy (V30), where the pericardium was operationally defined as the 0.5 cm shell of tissue around the heart itself. For patients with V30 &gt;46 percent, the risk of pericardial effusion was 73 percent at 18 months after therapy versus only 13 percent if the V30 was &le; 46 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older radiation therapy (RT) techniques used to treat patients with malignancies involving the thorax clearly caused an increase in cardiovascular morbidity and mortality. Such treatment involved exposure of large volumes of the heart to high doses of radiation. Although newer treatment techniques reduce both the dose of radiation and the volume of heart within the RT field, it is not clear whether the risk of late complications has been reduced in magnitude or simply delayed in the time to onset. However, a true reduction in severity is likely.",
"   </p>",
"   <p>",
"    Until there are long-term data on the cardiac toxicity associated with modern treatment approaches, we advocate a strategy of minimizing the chance of harm, based upon modifying both treatment- and patient-related risk factors whenever possible. The key components of this approach include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RT planning and treatment delivery methods that reduce both the volume and dose of incidental cardiac irradiation should be employed whenever possible. In patients with mediastinal lymphoma, standard fractionation (1.8 to 2 Gy per day) and equally weighted",
"      <span class=\"nowrap\">",
"       anterior/posterior",
"      </span>",
"      techniques (or other conformal techniques) should be used. &nbsp;",
"     </li>",
"     <li>",
"      For patients with favorable early stage disease, omitting RT is sometimes an option to minimize the risk of delayed cardiac toxicity.",
"     </li>",
"     <li>",
"      When RT is appropriate in addition to systemic chemotherapy, the minimum necessary total dose of anthracycline should be administered. For patients whose treatment requires an increased number of cycles of anthracycline-based chemotherapy, a lower dose of RT will probably decrease the risk of myocardial infarction, but the higher doses of anthracycline will increase the risk of congestive heart failure and valvular abnormalities.",
"     </li>",
"     <li>",
"      Because classical coronary heart disease risk factors such as smoking, elevated lipid levels, and hypertension appear to increase the risk of RT-induced heart disease, efforts should be made to screen for and reduce or eliminate these risk factors in patients who have received cardiac irradiation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link\">",
"       \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      While no guidelines exist specifically for those who received chest irradiation, consideration should be given to cardiac perfusion imaging",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      coronary calcium scoring by CT if coronary arteries received &gt;35 Gy of irradiation exposure beginning five years after therapy or after age 30 to 35 years, whichever is last. Screening with one of these modalities is especially encouraged for survivors at high risk based upon other coronary artery disease risk factors. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24970?source=see_link\">",
"       \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30410?source=see_link\">",
"       \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In those survivors who received &gt;300",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      of anthracyclines as part of their treatment, non-invasive screening with nuclear imaging",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      echocardiography should also be encouraged to evaluate cardiac function and valvular status. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/1\">",
"      Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994; 12:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/2\">",
"      Hooning MJ, Aleman BM, van Rosmalen AJ, et al. Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. Int J Radiat Oncol Biol Phys 2006; 64:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/3\">",
"      Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 2000; 355:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/4\">",
"      Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/5\">",
"      Hardenberg, PH, Munley, MT, Hu, C, et al. Doxorubicin-based chemotherapy and radiation increase cardiac perfusion changes in patients treated for left-sided breast cancer. Int J Radiat Oncol Biol Phys 2001; 51:S158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/6\">",
"      Heidenreich PA, Hancock SL, Vagelos RH, et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J 2005; 150:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/7\">",
"      Orzan F, Brusca A, Gaita F, et al. Associated cardiac lesions in patients with radiation-induced complete heart block. Int J Cardiol 1993; 39:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/8\">",
"      Larsen RL, Jakacki RI, Vetter VL, et al. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 1992; 70:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/9\">",
"      Moslehi J. The cardiovascular perils of cancer survivorship. N Engl J Med 2013; 368:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/10\">",
"      Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/11\">",
"      Giordano SH, Kuo YF, Freeman JL, et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005; 97:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/12\">",
"      Jones JM, Ribeiro GG. Mortality patterns over 34 years of breast cancer patients in a clinical trial of post-operative radiotherapy. Clin Radiol 1989; 40:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/13\">",
"      H&oslash;jris I, Overgaard M, Christensen JJ, Overgaard J. Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet 1999; 354:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/14\">",
"      Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005; 6:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/15\">",
"      Patt DA, Goodwin JS, Kuo YF, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol 2005; 23:7475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/16\">",
"      Paszat LF, Mackillop WJ, Groome PA, et al. Mortality from myocardial infarction following postlumpectomy radiotherapy for breast cancer: a population-based study in Ontario, Canada. Int J Radiat Oncol Biol Phys 1999; 43:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/17\">",
"      Doyle JJ, Neugut AI, Jacobson JS, et al. Radiation therapy, cardiac risk factors, and cardiac toxicity in early-stage breast cancer patients. Int J Radiat Oncol Biol Phys 2007; 68:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/18\">",
"      McGale P, Darby SC, Hall P, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol 2011; 100:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/19\">",
"      Taylor CW, Br&oslash;nnum D, Darby SC, et al. Cardiac dose estimates from Danish and Swedish breast cancer radiotherapy during 1977-2001. Radiother Oncol 2011; 100:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/20\">",
"      Hooning MJ, Botma A, Aleman BM, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007; 99:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/21\">",
"      Vallis KA, Pintilie M, Chong N, et al. Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. J Clin Oncol 2002; 20:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/22\">",
"      Nixon AJ, Manola J, Gelman R, et al. No long-term increase in cardiac-related mortality after breast-conserving surgery and radiation therapy using modern techniques. J Clin Oncol 1998; 16:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/23\">",
"      Harris EE, Correa C, Hwang WT, et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 2006; 24:4100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/24\">",
"      Correa CR, Litt HI, Hwang WT, et al. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol 2007; 25:3031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/25\">",
"      Jagsi R, Griffith KA, Koelling T, et al. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer 2007; 109:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/26\">",
"      Bouchardy C, Rapiti E, Usel M, et al. Excess of cardiovascular mortality among node-negative breast cancer patients irradiated for inner-quadrant tumors. Ann Oncol 2010; 21:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/27\">",
"      Prosnitz RG, Hubbs JL, Evans ES, et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. Cancer 2007; 110:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/28\">",
"      Seddon B, Cook A, Gothard L, et al. Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy. Radiother Oncol 2002; 64:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/29\">",
"      Cowen D, Gonzague-Casabianca L, Brenot-Rossi I, et al. Thallium-201 perfusion scintigraphy in the evaluation of late myocardial damage in left-side breast cancer treated with adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 1998; 41:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/30\">",
"      Gyenes G, Fornander T, Carlens P, Rutqvist LE. Morbidity of ischemic heart disease in early breast cancer 15-20 years after adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 1994; 28:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/31\">",
"      H��jris I, Sand NP, Andersen J, et al. Myocardial perfusion imaging in breast cancer patients treated with or without post-mastectomy radiotherapy. Radiother Oncol 2000; 55:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/32\">",
"      Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109:3122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/33\">",
"      Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/34\">",
"      Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/35\">",
"      Mauch PM, Kalish LA, Marcus KC, et al. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1995; 1:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/36\">",
"      Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008; 49:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/37\">",
"      Galper SL, Yu JB, Mauch PM, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2011; 117:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/38\">",
"      Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007; 99:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/39\">",
"      Lee CK, Aeppli D, Nierengarten ME. The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience. Int J Radiat Oncol Biol Phys 2000; 48:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/40\">",
"      Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993; 11:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/41\">",
"      Reinders JG, Heijmen BJ, Olofsen-van Acht MJ, et al. Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. Radiother Oncol 1999; 51:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/42\">",
"      Boivin JF, Hutchison GB, Lubin JH, Mauch P. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 1992; 69:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/43\">",
"      Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21:3431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/44\">",
"      Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004; 22:3139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/45\">",
"      Heidenreich PA, Hancock SL, Lee BK, et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 2003; 42:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/46\">",
"      Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 2003; 290:2831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/47\">",
"      Wethal T, Lund MB, Edvardsen T, et al. Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study. Br J Cancer 2009; 101:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/48\">",
"      Adams MJ, Hardenbergh PH, Constine LS, Lipshultz SE. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 2003; 45:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/49\">",
"      Carlson RG, Mayfield WR, Normann S, Alexander JA. Radiation-associated valvular disease. Chest 1991; 99:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/50\">",
"      Carmel RJ, Kaplan HS. Mantle irradiation in Hodgkin's disease. An analysis of technique, tumor eradication, and complications. Cancer 1976; 37:2813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/51\">",
"      Lipshultz SE, Adams MJ. Cardiotoxicity after childhood cancer: beginning with the end in mind. J Clin Oncol 2010; 28:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/52\">",
"      Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 2010; 28:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/53\">",
"      Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009; 339:b4606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/54\">",
"      Wei X, Liu HH, Tucker SL, et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys 2008; 70:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/55\">",
"      Martel MK, Sahijdak WM, Ten Haken RK, et al. Fraction size and dose parameters related to the incidence of pericardial effusions. Int J Radiat Oncol Biol Phys 1998; 40:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/56\">",
"      Konski A, Li T, Christensen M, et al. Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. Radiother Oncol 2012; 104:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/21/34137/abstract/57\">",
"      Tripp P, Malhotra HK, Javle M, et al. Cardiac function after chemoradiation for esophageal cancer: comparison of heart dose-volume histogram parameters to multiple gated acquisition scan changes. Dis Esophagus 2005; 18:400.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7062 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-F35B292492-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_21_34137=[""].join("\n");
var outline_f33_21_34137=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BREAST CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Initial evidence of cardiovascular toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Contemporary RT techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Randomized trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Effect of radiation dose to the heart",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Surrogate endpoints of myocardial injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Breast cancer summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HODGKIN LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Incidence of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mortality from myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Cardiomyopathy and diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Valvular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Conduction defects and autonomic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Risk factors in HL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PEDIATRIC PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ESOPHAGEAL CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42232?source=related_link\">",
"      Cardiotoxicity of trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30106?source=related_link\">",
"      Management of locally advanced unresectable esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/6/32874?source=related_link\">",
"      Overview of Hodgkin lymphoma in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/34/36394?source=related_link\">",
"      Overview of the approach to the adult survivor of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13512?source=related_link\">",
"      Overview of the treatment of classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=related_link\">",
"      Postmastectomy chest wall irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=related_link\">",
"      Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39657?source=related_link\">",
"      Techniques of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11770?source=related_link\">",
"      Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_21_34138="DMERC 484 LTOT form B";
var content_f33_21_34138=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    DMERC 484 LTOT form B",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 727px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_21_34138=[""].join("\n");
var outline_f33_21_34138=null;
var title_f33_21_34139="Obstetrical gynecologic history";
var content_f33_21_34139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessment of past obstetrical and gynecologic history",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Past obstetrical history",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Date of delivery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gestational age at delivery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Location of delivery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sex of child",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Birthweight and percentile for gestational age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mode of delivery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Type of anesthesia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Length of labor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Outcome (miscarriage, stillbirth, ectopic, etc)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Details (eg, type of hysterotomy incision, forceps, etc)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Complications (maternal, fetal, child)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Gynecologic history",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Age at menarche",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Date of last menstrual period",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Date of previous menstrual period",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cycle length and duration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Type of contraception",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sexually transmitted infections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gynecologic surgery or disorders (eg, cervical, uterine, or ovarian surgery; endometriosis, fibroids, uterine anomalies)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_21_34139=[""].join("\n");
var outline_f33_21_34139=null;
var title_f33_21_34140="Rush VIT - three day protocol";
var content_f33_21_34140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F80931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F80931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Three-day rush schedule for Hymenoptera venom immunotherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Day",
"       </td>",
"       <td class=\"subtitle1\">",
"        Volume (mL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Concentration (micrograms/mL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose (micrograms)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The time interval between doses on days one and two is 15 minutes. Once the maintenance dose of 100 micrograms is reached, it is then given at one-week intervals for two doses, then two-week intervals for two doses, then three-week intervals for two doses, then monthly thereafter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Goldberg A, Confino-Cohen R. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy. Ann Allergy Asthma Immunol 2003; 91:405. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_21_34140=[""].join("\n");
var outline_f33_21_34140=null;
var title_f33_21_34141="Thoracic ultrasound - Absence of lung sliding";
var content_f33_21_34141=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PULM/77394/Thorac_US_lung_slide_conv.mp4?title=Thoracic+ultrasound+-+Absence+of+lung+sliding\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thoracic ultrasound: Absence of lung sliding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 272px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEQAUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApaSvZfgRPpUVhqInkto9TMoOZWUMYtoxtz2znOPbPamld2Ma9X2MHO1zxqiux+K8mmy+NLttIMJi2J5hhxsMmPmxjj0zjvmuOpPQ0hLnipdwooooKCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAClpKKACiiigAooooAKKKKAJFVCOXwfpTDjPBzSUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABS4NSRQSygmKNmA7gVM8VxAN0kRC8ckUARRW00pxHG7fQU77HN3THOOatreXKxgQxldx6461N/Z2qSKjtG2OooAbBpDS2SzKSXLYK56Co5NLmCqUj6nqTTorfULZwAHVScHnjmu9sPBUj6AZ57zMhG9cHigDziaymjLbgOOTg1UrQvllhvJYB8zfdI61VNvPtP7p8D/ZoAhoqRonX7y4pmDQAlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFKQR1pKACiiigAoope1ACUq4DDPSkooA7HQfEVvZw+U1vHtY4GRzW3eXNvqNu0MVuFkxn7vFed23MwABLHheO9bQ1i+tW8hI1ZhwTjrQBotaXLxCSGJGIP3B7VoR39/MI4YrVhxzntWboWoXlkxaePzAxPGOlbVlPez3jssJVHHykdqAMO+g1I3BFwUTePlAq/9q1a10cp9sUoowBjpVLxHBqcdwG83fjtjGKxLwXiQnzbgkH7yUAbvhfTrS8uGubu5MkueQa3taktLOBo4QnzDAzXOeEbZbbUEnnVjCeQT0Ndvd6ZaanMsuwCIdvU0AebJYXV+HMUe7aSeOeKdZw4he2ljXcByR1r2Pw/oItlK29m3lvxnGc1S1zwmlnNLPKnlBxwMUAeLzWEyEEISpPFIbCdSNyHBru9X+xJabU2lgcZ9K529v44UKk727Y7UAc+yBdwYncO1R0+VzJIWPU0ygAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApafAP3q5qS52lwF60ARKex70Ou0j3odCmMnmrVhHFK7ee2COmaAKVFSyoolYKRgHimBSelADasWzRKGMq7vQVCqljhQSfap47OaSZYhGwc+ooAhALsdqn8KFQuSFFdDZaQ1vOVmbPGT7UsmjO0jNb/dPXFAFK0jRngAX5ga2orS4lnV4Yt2DyCOtXdO0uC008vIC0oGQe9bXg+zmunW5bO0H+HvQBCv2hEVZbF/XIWrkmoTQYiW2Cybcgn0rc8QamYoPLW2lz03beK5ZdQumn8x7OQgDAJHWgCxd21zfiIsnzuQG44AqLWPCSgPIWwCgPrmm3uralujijt3iibnfjpWraX7FFEzSTNjlcZxQBj2ugtNabYpWwora0qaFYzA7jdGMdaZNezW9tKsdu8SuCQXrmLaL91c3CyMknoeM0Aes+GPFH2FWjn2qg+6+M1neNPFS3unuEUOe7dyK80g17yrQK5J9zTZNaSSBhsyVGcetAFC7tWnI8p+GOcGs28sZd2M4Yda1tDuIhcGeUFyc4XstaF9sljLhQCx+9QBwz20qglh0qCuq1GO2ityBIHkI5I6CuWbqaAEpe1JRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFKOtJRQBaii3nKEc9jSPBIr5dTUUMhicMK0ZrxJIBgjcKAFTTmnCvE+4Y6Uq6cWJBO0k85qvZ6lLa5AAarUerGSTMijntQBr6f4WgkIM0+4HsDXQnwxpcVsNzY9649NTIkKBjjqKtHVZQqqspOOqk0Adp4c8L6VLM77hlRxntV3VvDdtZRpdJIHbG4jHauW0rUpLplWImHH3vU1tvfIX/eSyNxjB5FAA2nW1zEryRiPdzknmr0fh+ICNrK4/eN8v4VkteO8irKB5UZyvqa6nTLsNatKke3A4JoAyNP0f8AfzRtcrLJnGCMCum0rTZLLy1hkRFZgNvasKWEXcvmQqY5B3XvUv8ApVrMheVpFXnbQB02o6fJcsN0yiAHB461Q1Gxitdsfmh2xwOM06LVZprMReVhieM1Pd2WLYS3CAzEcHPNAFO0srLeDcyb2/uk9Kq6lfafp5n+zxrlBkkCqskK2tx5+9yx/h60660ubU4JHMEiAjrt+9QBnWV3Lq6s7ACAH5QepqlqNv5q+XGqAjPBPWtDS/D15YRM4YrbnsT0rY0zwub6YmWIYz97OM0Aea6rpCvb+Y2Yyo6Ketc7Crx7ziRx05Fe76v4UtgiwOAeeg7VWk8HwtHsjhRVA+81AHi+lrIjOXHloTVq+vViiKQyZTuDzXUeJrSy0wmKNQ8vTIrjWhWTc8i4wckUAZMssjZDMSpqKtOWBJLdpAOn6VmEHuKAEooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAJlcBePve9bGjacJmDTNyeQM1jrCSowMk10GgRsk8YmOOc4oA6NNLddgjTA6g55rUs9LmnkQWqF5v4hW/bW0U9orq4UYra8NtY2UuZJAG9c0AcVf6TMk22ZDE4612+gaXbvZogkDBlwVzUHi7VrS5nSO0KO2OSK521vmtd0iyfP2xQB6hpnhqztizhVYY4yelRyaZYtJIrQqoPR8d642x169EWJJGUEfxGtnRJLi8QmWQsAcg5oA1brSLWJF8pwHTn60XOlGLyrmR1myMbT0FU9TkiSIidtr9iDxTYb0fZxudiF6fN1oArG0eS+IUKNxzhRnbXSQ7oI0j2Mx7nAxVSDWrNI8mFd+OeKoNqv713VyO4WgDamsreVcSIRzllB4+tTSwWmmgSmUBSOAT0rjrnxIFY+Y7EnjA5rHvr83w5Z39Ax6UAdDrfiOztiTH88hPrXMXniG9khlkUbQeAM1iaurQP5u4FsdPSsB9QmnlEYBC92BoAq600skvmvlyeSc9Kykb7QhUjHPNXdYuIlGxXKjvWW0626AqwOaALc7pbwiJY8k96wZQHZ2LAY6Ct+wt11ZxvYiMda07fw5FcSN5ZXYvf0oA4bGQTSVta3Ba2UjwxDdN6+lYtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBbs0d3Ugniuss9Ilv4Fe3OXX0PNcvpzASpufap4rqbOeXTpVljkbBoA6fSILyCIJIZGUdQTWlPoouoGeG5kRyM4FZdrqM1yBIrZY9a1kvTbxdQG9KAOekefTWMdwA5z97vVmJ4JTHNkrg9Kh1spfSCRmCsPTpVaElUVD8yrySO9AHRyX8bqRNGdmMAin6TqNxbtsgk/dn1qjazRTcYzjpVho1g+fcoHpQBp39zLNFmVw30NFhI91b5L4RegzWJM4VvMaVmjP8ADnioxrKQMYoeFPGccCgDq/MSK1LSTKCOgFVbObzZiyNu96w7mS3mty29zJj14qGyuJLW2++NxPAoA3prdmdiwxznIrOvovIBmgYs3cZ4pn26YIwfncOeaznebrnCehNAAYkuVaa4kYEfwk1UMKTNgEIg9O9N+aSdwfuDvVcRxpI7mVh6KDxQBj+ILWOKRWBz9a5y7GJAAcjFbGtyu8w2Mdue9ZckixHAAY+tAF7SpDHb7EfZnqfStlfEsVnaNBDlmAxn1rji7Ek5IzTaAJbmZ7id5ZDlmOaioooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKWkooAlhb5gB3rfW8mMCxPImAOcjmucBwQRWnBIHK4OT05oA6jTdUjt7XCOC3pUiar5koaTJQ1zwhEYJjGd3BFTpsUqrcCgDbnnSUkRKWzUtvK6KAU2n3qGCWCKIcjd71XvpnlGYic+1AFkXvl3ZXdtPrWtYbrwM0zsV7VhJbxm2ZpB83U+tTWOoyQERn/VdjQBvowhjMSpuA9aLWJbgSqyquaoRah5rliy5XipEvzvClCM/xY4oAXyTGGjALgdyaUtFhVKOcU57hkHykEe1NiviOHjG31oAledFHMY2+uc1HLzCxQA5qnJceZOwRMA+gpplEP3gwSgCJkIGzeVLcnmsXULgwny48g+pqbUr5Wk3xMRj171l3H+lFd78+mKAElnV4CSC59hWXMUYZGQfStu3ighiIduDWJd+X57eVytAEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUtJQAo608ORIGGaFjLKSO3apIcIN5x+NAG3Zy7owxXAAq0UF4uYyuBWXbyuwIBGD2p1lvhmYbyO+KALz2skUgLEup689KPPCybFOGFPadiMseO9RHypHEiDnucUAXLS6kkdopACT0pzKYiwlK47VDCGjJkB6D0qK5eScAkcd8daAJ4mVnzGCBnr2rYim3hYieD3BrGC7IVCZ+hpIpwJhvl2Y7YoA6UWwZduX6dRTGgcIU4x6ms5NUmjXZCDID3pxuLhV3TIWJ96ALaPHagKSGJ4BrP1EOqllyc9qT7Q8zLuiOAc/SrplUxdVIA70AcxJCzyNJLnIHA7VUg3qr7U+Y9ya3jLbyOVncewFQ3MUPlt5O0DtQBz7pLkhiSe4FVZY9pwAa04FEUjGaQHPaq1y6Fjhh7CgChRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFLSUUAOVipyDQTmm04DjNAFu1ljjCsTzVo3IeUYjJHrWZxt+Uc1fsGBABYBvegC4bgIQGzj0NXILqOVsAAVBJaidOcE+1RWlp5UvIOKANISyEldwC+4q7aQRKwdnVqybkbcbc49jSwtlRtBPrQBsXbq3yqg+tU3s4XXcWUP9KrzO6FQp61YRhFtaToe1AGrYRRrAOhYelR3V4sTsAM0lrcedIFT5PwpL+DzIyTtGOc0AZE+o5l28rmo5JiUwGPPvUYnjabY65I9qlkVDyBigCKNIUOWGW9Saoaizs2In+XvzTLt5BIQmCT3FV1Z1B3HI75oAryEk88kd6VUyKeMMCSPwFRZIPFACHg0lFKaAEooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAHKM0GjdgYFKEJGaAHbsRhQOtXbCB3kGdrKfeq6xgRjdUUbMjZVyB7UgOkWCWHHlLkHrzVhVDgFmw3cGsm3vWSPlyTSvLI53Ak+wpgaMqbQTwaht5djj5cA+9RLIxTuD706J92Mjp3oAviRFBZgD6ZrNmnZ5ec+wq+BHIuGx+NVJYlVwQc+nPSgDSs1SWPLMysOwouHCIVGefXvVGIHcCpIPqDUlzceWmW+fFAFKa32P5gOPWi4kby+M/Wnljd4JG1ake3wnXIFAGK04R/wCdSyRpImc8+1SXUUCr0wx61HHaMyjykY57k0AUOQCFNNrRmthDH8w+Y1QK9hyaAGUU9Av8RppxnjpQAlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRS0UAJRRRQAUUUUAFFFFABUscm3g81FT1UsOMcUAWg0JTliD6VPaeQ/yFSfTis5UO7DAirkJMIBUg/WgDWS1VRzt2n1FWoLL+46/nWFJePJ8rHbj0NNW7P3cuG9c0AbdzYMTkkE+1RfZxGv8ArCD71UtbiQDLuT9TU8txE4yQ26gBzZBCg9e9OAO3D8+4qEuSo2HGPWrEBO3525oAhDMG25O2nTFdmOcEetSBcnOBj60ycAD5QPqaAK3lOADHuVfepC8rfKpOaXzNiYbAFU1mLS/u3yelAE8kW1cty3qaZFdsp2qcn2pfLlyTM4x6VRuJgkmI+1AEtzcGVyDw3vVJ12dDTXYsxPrTaAFzSUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFKaSgApRSUUAFFFFABRRRQAUUUUAFLmkooAerAEZJ/CnSSluAeBUVFAE6Ybk9aXy8t8rCq9KCR0NAGjFJ5IHmYxViV4po8x8H2rIMrEYJqZLt0XChPyoAtNLsO0mnpcIwKliDWdJPI/U/lSJIVPAoA0UufLk7uKsSX25PuED61jPIWOen0pmT60AXbq4MvUcelVA5DArwfakDsBgHim0ATPK7L8zEmoaKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAU0lLRQAlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFLRQAlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAtFJRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_21_34141=[""].join("\n");
var outline_f33_21_34141=null;
var title_f33_21_34142="Long-acting meds for ADHD in children";
var content_f33_21_34142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intermediate- and long-acting medications for children with attention deficit hyperactivity disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        US trade name",
"        <br/>",
"        (generic availability)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description of release and duration of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial dose*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose advancement",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximum dose",
"        <br/>",
"        (per day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Methylphenidate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate-SR",
"        <br/>",
"        (20 mg tablets)",
"       </td>",
"       <td>",
"        Ritalin-SR (generic available)",
"       </td>",
"       <td>",
"        Delayed onset with continuous release over 3 to 8 hours. May require twice daily dosing and/or use with immediate-release methylphenidate.",
"       </td>",
"       <td>",
"        20 mg",
"       </td>",
"       <td>",
"        Increments of 20 mg per day every 3 to 7 days",
"       </td>",
"       <td>",
"        <p>",
"         &le;50 kg: 60 mg",
"        </p>",
"        &gt;50 kg: 100 mg",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate ER",
"        <br/>",
"        (10, 20 mg tablets)",
"       </td>",
"       <td>",
"        Metadate ER (generic available)",
"       </td>",
"       <td>",
"        Delayed onset with continuous release over 3 to 8 hours. May require twice daily dosing and/or use with immediate-release methylphenidate.",
"       </td>",
"       <td>",
"        10 mg",
"       </td>",
"       <td>",
"        Increments of 10 mg per day every 3 to 7 days",
"       </td>",
"       <td>",
"        <p>",
"         &le;50 kg: 60 mg",
"        </p>",
"        &gt;50 kg: 100 mg",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate LA",
"        <br/>",
"        (10, 20, 30, 40 mg capsules)",
"       </td>",
"       <td>",
"        Ritalin LA (generic available except 10 mg)",
"       </td>",
"       <td>",
"        <p>",
"         50 percent immediate-release and 50 percent delayed-release over 8 to 12 hours (bi-modal).",
"        </p>",
"        Capsule may be opened and contents sprinkled over spoonful of cold applesauce or other thick substance (eg, peanut butter); capsule should not be crushed or chewed.",
"       </td>",
"       <td>",
"        10 or 20 mg",
"       </td>",
"       <td>",
"        Increments of 10 or 20 mg per dose every 3 to 7 days",
"       </td>",
"       <td>",
"        <p>",
"         &le;50 kg: 60 mg",
"        </p>",
"        &gt;50 kg: 100 mg",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate CD",
"        <br/>",
"        (10, 20, 30, 40, 50, 60 mg capsules)",
"       </td>",
"       <td>",
"        Metadate CD",
"       </td>",
"       <td>",
"        <p>",
"         30 percent immediate-release and 70 percent delayed-release over 8 to 12 hours (bi-modal).",
"        </p>",
"        Capsule may be opened and contents sprinkled over spoonful of cold applesauce or other thick substance (eg, peanut butter); capsule should not be crushed or chewed.",
"       </td>",
"       <td>",
"        20 mg",
"       </td>",
"       <td>",
"        Increments of 10 mg per dose every 3 to 7 days",
"       </td>",
"       <td>",
"        <p>",
"         &le;50 kg: 60 mg",
"        </p>",
"        &gt;50 kg: 100 mg",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate ER",
"        <br/>",
"        (18, 27, 36, 54 mg tablets)",
"       </td>",
"       <td>",
"        Concerta (generic available)",
"       </td>",
"       <td>",
"        <p>",
"         20 percent immediate-release and 80 percent continuous-release over 10 to 12 hours by osmotic delivery.",
"        </p>",
"        Tablet must be swallowed whole.",
"       </td>",
"       <td>",
"        18 mg",
"       </td>",
"       <td>",
"        Increments of 9 to 18 mg per dose every 3 to 7 days",
"       </td>",
"       <td>",
"        <p>",
"         &lt;13 years: 54 mg",
"        </p>",
"        &ge;13 years: 72 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate XR oral suspension",
"        <br/>",
"        (5 mg/mL)",
"       </td>",
"       <td>",
"        Quillivant XR",
"       </td>",
"       <td>",
"        20 percent immediate-release and 80 percent extended-release for duration of action up to 12 hours.",
"       </td>",
"       <td>",
"        20 mg",
"       </td>",
"       <td>",
"        Increments of 10 mg every 7 days",
"       </td>",
"       <td>",
"        60 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate patch",
"        <sup>",
"         &Delta;",
"        </sup>",
"        <br/>",
"        (10, 15, 20, 30 mg patch)",
"       </td>",
"       <td>",
"        Daytrana",
"       </td>",
"       <td>",
"        Onset 2 hours after application of patch and continuous release over 10 to 12 hours.",
"       </td>",
"       <td>",
"        10 mg",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Increments of 5 mg per dose every 3 to 7 days",
"       </td>",
"       <td>",
"        30 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Dexmethylphenidate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dexmethylphenidate XR",
"        <br/>",
"        (5, 10, 15, 20, 25, 30, 35, 40 mg capsules)",
"       </td>",
"       <td>",
"        Focalin XR",
"       </td>",
"       <td>",
"        <p>",
"         Fifty percent immediate-release and 50 percent delayed release over 10 to 12 hours (bi-modal).",
"        </p>",
"        Capsule may be opened and contents sprinkled over spoonful of cold applesauce or other thick substance (eg, peanut butter); capsule should not be crushed or chewed.",
"       </td>",
"       <td>",
"        5 mg",
"       </td>",
"       <td>",
"        Increments of 5 mg per dose every 3 to 7 days",
"       </td>",
"       <td>",
"        40 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Amphetamines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dextroamphetamine SR",
"        <br/>",
"        (5, 10, 15 mg capsules)",
"       </td>",
"       <td>",
"        Dexedrine spansule (generic extended-release available)",
"       </td>",
"       <td>",
"        Combination of immediate- and continuous-release over 6 to 8 hours. May require dividing dose twice daily.",
"       </td>",
"       <td>",
"        5 mg",
"       </td>",
"       <td>",
"        Increments of 5 mg per day every 3 to 7 days",
"       </td>",
"       <td>",
"        <p>",
"         &le;50 kg: 40 mg",
"        </p>",
"        &gt;50 kg: 60 mg",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amphetamine-dextroamphetamine ER",
"        <br/>",
"        (5, 10, 15, 20, 25, 30 mg capsules)",
"       </td>",
"       <td>",
"        Adderall XR (generic available)",
"       </td>",
"       <td>",
"        Combination of immediate- and continuous-release over 8 to 10 hours.",
"       </td>",
"       <td>",
"        5 mg",
"       </td>",
"       <td>",
"        Increments of 5 mg per dose every 3 to 7 days",
"       </td>",
"       <td>",
"        40 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lisdexamfetamine",
"        <br/>",
"        (20, 30, 40, 50, 60, 70 mg capsules)",
"       </td>",
"       <td>",
"        Vyvanse",
"       </td>",
"       <td>",
"        <p>",
"         Prodrug converted to dextroamphetamine in bloodstream with an effect over ~10 hours.",
"        </p>",
"        Capsule may be opened and dissolved in water for immediate use.",
"       </td>",
"       <td>",
"        20 mg",
"       </td>",
"       <td>",
"        Increments of 10 or 20 mg per day every 3 to 7 days",
"       </td>",
"       <td>",
"        70 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Non-stimulants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"6\">",
"        Selective norepinephrine reuptake inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Atomoxetine",
"        <br/>",
"        (10, 18, 25, 40, 60, 80, 100 mg capsules)",
"       </td>",
"       <td>",
"        Strattera",
"       </td>",
"       <td>",
"        At least 10 to 12 hours",
"       </td>",
"       <td>",
"        0.5 mg/kg per day for minimum of 3 days",
"       </td>",
"       <td>",
"        Increase to 1.2 mg/kg per day after a minimum of 3 days (maximum 100 mg per day)",
"       </td>",
"       <td>",
"        Lesser or 1.4 mg/kg or 100 mg per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"6\">",
"        Alpha-2 adrenergic agonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Extended release guanfacine",
"        <sup>",
"         &sect;",
"        </sup>",
"        <br/>",
"        (1, 2, 3, 4 mg tablets)",
"       </td>",
"       <td>",
"        Intuniv",
"       </td>",
"       <td>",
"        At least 10 to 12 hours",
"       </td>",
"       <td>",
"        1 mg per day",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        Increments of 1 mg per day at no less than weekly intervals",
"       </td>",
"       <td>",
"        4 mg per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Extended release clonidine",
"        <sup>",
"         &sect;",
"        </sup>",
"        <br/>",
"        (0.1 and 0.2 mg tablets)",
"       </td>",
"       <td>",
"        Kapvay",
"       </td>",
"       <td>",
"        At least 10 to 12 hours",
"       </td>",
"       <td>",
"        0.1 mg at bedtime on days 1 through 7",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        Increments of 0.1 mg per day at no less than weekly intervals. For titration, divide dose twice daily, either equally or higher dose at bedtime.",
"       </td>",
"       <td>",
"        0.4 mg per day",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SR: sustained release; LA: long-acting; ER: extended release; CD: controlled dispense; XR: extended release.",
"     <br/>",
"     * Suggested doses for initiating treatment with long-acting stimulant medications for treatment of children aged &ge;6 years.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     This maximum dose exceeds the US Food and Drug Administration-approved maximum dose; careful monitoring for adverse effects is warranted.",
"     <br/>",
"     &Delta; Patch is applied 2 hours before needed effect and worn for a total of 9 hours. Doses for the methylphenidate patch are not equivalent to those for the oral preparations.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Doses above 40 mg per day total are rarely necessary and warrant close monitoring.",
"     <br/>",
"     &sect; Immediate-release form cannot be substituted mg for mg for extended-release due to pharmacokinetic differences. Discontinuation requires dose tapering to prevent rebound increase in blood pressure.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894.",
"      </li>",
"      <li>",
"       Subcommittee on attention-deficit/hyperactivity disorder, Steering committee on quality improvement and management. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Supplemental information. Pediatrics 2011.",
"      </li>",
"      <li>",
"       Drugs for treatment of ADHD. Treat Guidel Med Lett 2011; 9:23.",
"      </li>",
"      <li>",
"       Wender EH. Managing stimulant medication for attention-deficit/hyperactivity disorder. Pediatr Rev 2001; 22:183.",
"      </li>",
"      <li>",
"       Quillivant XR prescribing information. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2012/202100lbl.pdf (Accessed on November 15, 2012).",
"      </li>",
"      <li>",
"       Quillivant XR - An extended-release oral suspension of methylphenidate. The Medical Letter 2013; 55:10.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_21_34142=[""].join("\n");
var outline_f33_21_34142=null;
var title_f33_21_34143="Erysipeloid";
var content_f33_21_34143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erysipeloid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erysipeloid is the localized cutaneous form of the infection caused by Erysipelothrix rhusiopathiae. In this patient, violaceous maculopapular lesions of the fingers developed after cleaning fish.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lee T Nesbitt, Jr. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_21_34143=[""].join("\n");
var outline_f33_21_34143=null;
